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Abstract 
Background & Aims: Stromal targeting for pancreatic ductal adenocarcinoma (PDAC) is 
rapidly becoming an attractive option, due to lack of efficacy of standard chemotherapy and 
increased knowledge about PDAC stroma. We postulated that combining stromal therapy 
may enhance anti-tumour efficacy of chemotherapy. 
Methods: Gemcitabine and all-trans retinoic acid (ATRA) were combined in a clinically 
applicable regimen, to target cancer cells and pancreatic stellate cells (PSC) respectively, in 
3D organotypic culture models and genetically engineered mice (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre mice: KPC mice) representing the spectrum of PDAC. 
Results: In two distinct sets of organotypic models as well as KPC mice, we demonstrate a 
reduction in cancer cell proliferation and invasion together with enhanced cancer cell 
apoptosis when ATRA is combined with Gemcitabine compared to vehicle or either agent 
alone. Simultaneously, PSC activity (in the form of deposition of extra-cellular matrix proteins 
such as Collagen and Fibronectin), and PSC invasive ability were both diminished in 
response to combination therapy. These actions were mediated by affecting a range of 
signalling cascades (Wnt, hedgehog, retinoid and FGF were studied) in cancer as well as 
stellate cells, effecting myriad epithelial cellular functions such as epithelial-mesenchymal 
transition, cellular polarity and lumen formation. At the tissue level, this resulted in enhanced 
tumour necrosis, increased vascularity, and diminished hypoxia. Consequently, there was an 
overall reduction in tumour size.  
Conclusions: Stromal co-targeting (ATRA) alongside chemotherapy (Gemcitabine) is a 
potential clinical strategy. Experimental evidence suggests that the effect of this combination 
is mediated by dampening multiple signalling cascades in the tumour-stroma cross-talk, 
rather than ablating stroma or targeting a single pathway.  
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Introduction 
 Combination chemotherapy regimens consisting of oxaliplatin, irinotecan, 
fluorouracil, and leucovorin (FOLFIRINOX) 1 or nab-Paclitaxel with Gemcitabine 2 have 
resulted in increased median overall survival compared to Gemcitabine alone, which is the 
currently approved and widely used palliative mono-therapy 3. However, gains have been 
marginal, and this may well be because desmoplasia remains largely unaltered with 
therapy4. 
 PDAC is characterised by a pronounced desmoplastic stroma mediated by the 
activation of quiescent pancreatic stellate cells (PSC) 5. This stroma creates a uniquely 
hypoxic microenvironment that, paradoxically, promotes both tumour growth and metastatic 
spread while inducing vascular collapse, thus creating a barrier to the perfusion/diffusion of 
therapeutic agents6; which, altogether, makes this cellular desmoplastic stroma an appealing 
therapeutic target. The pharmacologic inhibition of the sonic hedgehog signalling pathway in 
combination with Gemcitabine, in a genetically engineered mouse model, LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice, produced variable results dependent on 
disease stage 7, 8, yet demonstrated proof-of-concept that stromal targeting was feasible. 
However, stromal ablation leads to a biologically more aggressive form of PDAC 8, 9, 
indicating that attention to the spatio-temporal aspects4 of the tumour-stroma cross-talk is 
critical for its effective targeting 10. 
 PSC play a central role in desmoplastic stroma11, 12. Previously, we demonstrated 
that restoring the quiescent state of PSC, by replenishing their physiological retinol depots 
using the pleiotropic agent: all-trans retinoic acid (ATRA), halted tumour progression through 
targeting multiple dynamic tumour-stromal signalling cascades 13, 14; a notion recently 
supported by targeting Vitamin D receptor 15. In this report, we used combination therapy to 
target pancreatic cancer cells and their supporting stroma in in vitro and in vivo PDAC 
models to demonstrate efficacy of this strategy. It is feasible to target and normalize multiple 
altered signalling cascades mediating tumour-stroma cross-talk with this approach. 
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Methods 
Organotypic cultures: 
 Short tandem repeat (STR) profiled cancer (Capan1, AsPC1) and stellate (PS1) cells 
were cultured, and pancreatic organotypic cultures were constructed as described elsewhere 
11, 16-18. Two cancer cell lines were utilised in organotypic models representing a spectrum of 
PDAC differentiation11, 13, 18. The pancreatic stellate cell line used was PS1, which was 
obtained from an unused normal pancreas (rejected for transplantation) donated by the UK 
human tissue bank (Ethics approval; Trent MREC (/MRE04/)). The cells were isolated in the 
laboratory, using the outgrowth method 19, 20 followed by immortalisation by expression of 
ectopic human telomerase reverse transcriptase (hTERT) 21, and verified as being of stellate 
cell origin by positive immunostaining for Desmin, Vimentin, αSMA and GFAP and ability to 
store Vitamin A 13.  
 In contrast to previous reports 13, 17, we allowed the cancer-stellate interaction to be 
established for 10 days 11, before commencing therapeutic dosing, for the treatment of an 
established tumour analogue. The cancer cell: st llate cell ratio was 1:2, as determined 
previously, providing the most aggressive, invasive phenotype within this model which 
mimicked histological features of advanced human cancer 11. Multiple biological and 
technical replicates performed by two independent researchers ensured reproducibility. 
Treatment was given for two cycles, as per the human clinical protocol 3, 22,. Briefly, 
treatment of organotypic cultures was performed daily with ATRA (Sigma R2625, St. Louis, 
MO, USA) at 1µM or with weekly Gemcitabine (2’, 2’-difluoro 2’-deoxycytidine, dFdC) (Eli 
Lilly, Indianapolis, IN, USA) at 100 nM (Capan-1/PS1) or 400 nM (AsPC1/PS1), or with the 
combination of Gemcitabine/ATRA or with respective vehicles. Organotypic cultures were 
harvested on day 24, fixed in 10% neutral buffered formalin (Cell Pathology BAF-001003A, 
Newton, UK), embedded in paraffin and cut into 4 µm sections. Each experiment had three 
technical replicates and at least three biologic repeats.  
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KPC mice treatment 
 All animal work was done in accordance with the UK Animals (Scientific Procedures) 
Act 1986, revised by the Amendment Regulations 2012 (SI 2012/3039) to transpose 
European Directive 2010/63/EU with approval from the local Animal Welfare and Ethical 
Review Body, and following the 2010 guidelines from the United Kingdom Coordinating 
Committee on Cancer Research 23. Compound mutant KPC mice with mature, established 
tumours were enrolled at a median age of 180 days and used as described previously 7, 13. 
ATRA was dissolved to 25mg/ml in dimethyl sulfoxide, further diluted to 2.98mg/ml in (2-
Hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich H5784) and finally to 1.5mg/ml with sterile 
filtered tap water. This ATRA solution was administered orally to mice at 15 mg/kg daily for 
seven days 13. Gemcitabine was injected intraperitoneally at 100 mg/kg on days zero, three 
and seven 7. The volume of the tumours was measured by ultrasound two days before the 
beginning of the treatment, and mice bearing tumour volume of ~250 mm3 (Supplementary 
Table 1) were selected for the study. Tumours were harvested seven days after beginning of 
the treatment, and immediately submerged in formalin for 24 hours, followed by embedding 
in paraffin blocks for further sectioning and immunostaining analysis. The primary endpoint 
of study was drug efficacy as measured by a number of surrogate markers. Survival was not 
an endpoint analysis. Samples of tumours and serum were also snap-frozen for analysis of 
drug concentrations using LC-MS/MS. 
 
Immunostaining  
 Paraffin-embedded sections were dewaxed and re-hydrated, and antigens were 
retrieved and immunostained for a range of markers to study cellular attributes using a range 
of antibodies (Supplementary Table 2) as described before 13, 16.  
 
Quantification  
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 The quantification of all cell counts and intensity of staining in the organotypic 
sections was performed on four-six representative pictures per organotypic gel of which 
there were three technical replicates for each of the biological repeats (minimum three). For 
the KPC mice, either the total tumour area or at least ten representative pictures per total 
tumour area were scanned using either Axioplan microscope (Zeiss 40 V 4.8.10, Carl Zeiss 
MicroImaging LLC, New York, US), confocal laser scanning microscope LSM 510 (Carl 
Zeiss MicroImaging LLC, New York, US) or Pannoramic 250 High Throughput 
Scanner  (3DHISTECH Ltd., Budapest, Hungary). The intensities of fluorescence in the 
green/red channels were normalised with IgG controls and background fluorescence and 
calculated in an unbiased, blinded manner using either Adobe Photoshop CS6 (San Jose, 
CA USA), or Pannoramic Viewer Software (3DHISTECH Ltd., Budapest, Hungary), and 
Image J software (NIH, Maryland USA) as described before 13. The methods for 
measurement of gel length and thickness, cancer and stellate total cell number per gel are 
described elsewhere 11. 
 
Tissue Gemcitabine and ATRA levels 
 Tissue samples were homogenized in 50% acetonitrile:water at a concentration of 
100 mg/mL using a precellys homogenizer.  An aliquot of the homogenate was precipitated 
with acetonitrile containing a stable isotope (5 deuterium) label internal standard of ATRA. 
Measurement was carried out against a calibration line prepared in mouse plasma 
homogenate (100 mg/mL) in 50% acetonitrile:water. The MS/MS used was a Sciex 
4000Qtrap equipped with a heated nebulizer atmospheric pressure chemical ionization 
source operating in the negative mode at 350ºC. MRM transitions were 301-205 and 306-
205 for unlabelled and labelled ATRA respectively. LC was performed using a Dionex 
Ultimate 3000 LC and autosampler, using a gradient separation on a Phenomenex Kinetex 
2.6 µm, 150x2.1 mm column. The binary gradient was run at 0.2 ml/min, starting at 40:60 
A:B changing to 10:90 A:B from 0-15mins then holding from 15-17.6 minutes before quickly 
ramping back to 40:60 A:B at 17.62 minutes. The LC-MS/MS system was controlled by 
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Analyst 1.4 software. In order to ensure the correct isomer (ATRA) was measured a system 
suitability test was run at the beginning and end of the sample analysis to demonstrate 
separation of the ATRA isomer from the 9- and 13-cis isomers of retinoic acid (data not 
shown). 
 Fresh frozen tumour and plasma samples were processed and analysed for 
Gemcitabine and its metabolites by LC-MS/MS as previously described 24. Briefly, LC-
MS/MS  was performed on a TSQ Vantage triple stage quadrupole mass spectrometer 
(Thermo Scientific, USA) fitted with a heated electrospray ionization (HESI-II) probe 
operated in positive and negative mode at a spray voltage of 2.5 KV, capillary temperature of 
150ºC. Quantitative data acquisition was done using LC Quan2.5.6 (Thermo Fisher 
Scientific, USA).  
 
Statistical analysis 
 Statistical analysis and graphical data representation were performed using the 
software PRISM V.6 (Graphpad, La Jolla, USA). Summary data are expressed as the 
median with interquartile range since the distribution was non-Gaussian. Comparisons were 
performed using Kruskal-Wallis test with Dunn’s multiple comparison test. The level of 
significance was set at P < 0.05.  
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Results  
 Dosing schedule and timing for treatment of organotypic cultures and KPC mice with 
Gemcitabine and ATRA were designed to mimic clinically relevant treatment regimens for 
advanced human pancreatic cancer based on previously available data 3, 7, 11, 13, 22. In vitro 
optimisations such as growth inhibition to 50% of control (GI50) levels for Gemcitabine were 
determined for translation into the organotypic 3D model. Interestingly, we found the 
presence of extra-cellular matrix (ECM) protein in 3D model to have preferential 
cytoprotective effect on the pancreatic stellate cells (PSC). This resulted in different GI50 for 
both PSC and cancer cells in 3D models compared to 2D culture (Supplementary Figures 1, 
data not shown). Previously we had demonstrated ATRA had no direct effect on cancer cells 
by performing PSC or cancer cell alone organotypic cultures 13. 
 We then sought to identify effects on the cancer cells and stellate cells separately 
within this experimental design mimicking advanced PDAC. There was no change in gel 
contractility in organotypic cultures with any of the agents as compared to vehicle treatment 
(Supplementary Figure 2). 
 There was a significant reduction in proliferation of cancer cells induced by the 
presence of ATRA either alone or in combination with Gemcitabine in vivo as well as in vitro, 
across all experimental conditions (Figures 1A-C, Supplementary Figures 3A and B).No 
significant difference was noted for stellate cells proliferation after any of the treatments 
(Supplementary Figure 3C). However, induction of apoptosis was more pronounced with 
introduction of ATRA in the combination arm, suggesting that Gemcitabine potentiates the 
effect of ATRA (Figures 1D-F, Supplementary Figure 3D and E). We did not find any 
significant difference in the apoptotic index of stellate cells after any of the treatments, in 
both PDAC models (Supplementary Figure 3F). Cancer cell invasion into the extra-cellular 
matrix, a surrogate marker for metastatic capability, was also reduced by the combination 
treatment (Figures 2A-B, Supplementary Figure 4A-B). 
 PSC invasion into the ECM, and stellate cell density in mouse tumours, were 
reduced by ATRA treatment alone, and in combination with Gemcitabine (Figures 2C-E, 
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Supplementary Figures 4A-C). PSC numbers within organotypic gels did not change, 
reflecting the protective effect of matrix proteins on PSC in 3D, not seen in 2D in vitro state 
(Supplementary Figures 1B and 2D-E). However, the PSC activation state was altered by 
ATRA and the combination of Gemcitabine and ATRA, as indicated by a significant reduction 
in deposition of extra-cellular matrix (ECM) substrates such as Fibronectin and Collagen I, 
implying stromal re-modelling (Figures 3A-D, Supplementary Figures 5A-C). 
 Together with stromal re-modelling, we demonstrated increased vascularity of the 
KPC tumours, associated with decreasing hypoxia (Figures 3E, 3F, Supplementary Figures 
6A, 6B). Surprisingly, despite this reduction in hypoxia, there was increased necrosis, in 
vivo, with combination treatment (Figure 4A, Supplementary Figure 6C). This resulted in 
smaller tumours in mice treated with combination therapy (Figure 4B). Certainly, with this 
regimen, both agents can be delivered successfully in vivo into the tumour parenchyma as 
measured by LC-MS/MS (Figures 4C-E). Furthermore, the tissue ATRA (not 9-cis and 13-cis 
RA) is directly correlated to serum ATRA measurements allowing surrogate measurements 
to be easily and readily performed (Figure 4C). 
 The precise mechanism(s) underpinning the success of this combination therapy are 
difficult to pinpoint, since ATRA influences multiple signalling cascades 13. The enhanced 
apoptosis and reduction in proliferation of cancer cells may result from the reduction of Wnt 
signalling in the tumour compartment 13, disrupted fibroblast growth factor (FGF) signalling in 
the stromal compartment 17, or targeting of other signalling cascades such as Hedgehog, 
IL6, and CXCL12 amongst others 14.  
 In our experimental models, we could demonstrate a reduction in nuclear 
translocation of FGF2 and FGFR1 in PSC upon treatment of KPC mice and organotypic 
cultures with ATRA (Figures 5A-F, Supplementary Figures 7,8); this co-translocation being 
pertinent to PSC activity as demonstrated before 13. There was enhanced nuclear Retinoic 
Acid Receptor β (RARβ) visibility within the PSC in KPC tumours upon treatment with ATRA 
(Figure 5G, Supplementary Figure 9A), which is known to reflect PSC quiescence 13. 
Upregulation of PSC RARβ activity enhances secretion of secreted Frizzled related protein 4 
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(sFRP4) from the quiescent PSC as demonstrated before 13. We could demonstrate 
increased stromal sFRP4 upon treatment with ATRA (Figure 5H, Supplementary Figure 9B). 
This modulation within PSC upon treatment with ATRA, in turn, led to reduced nuclear β-
catenin, which translocates to the nucleus following canonical Wnt signalling activation 13, 25 
(Figure 6A, Supplementary Figure 10). sFRP4 can sequester Wnt ligands within stroma to 
abrogate canonical Wnt signalling flux, and also act as gatekeeper, and, thus, affect 
epithelial-mesenchymal transition (EMT), apoptosis and invasion within cancer cells 26, 27.  
 In addition, there was reduction in Ezrin expression (Figure 6B, Supplementary 
Figure 11), which has previously been shown to enhance podosomal rosette formation 25. 
Ezrin is also a marker for lumen formation and apico-basal polarity and such changes could 
be observed in the organotypic cultures more clearly than KPC mice but were difficult to 
quantify (data not shown). Furthermore, there was suppression in the expression of EMT 
activating transcription factors, as evidenced by reduction of nuclear Twist1 and Zeb1 in 
PDAC cells (Figures 6C and D, Supplementary Figures 12, 13), which may be related to 
reduction of canonical Wnt signalling 28. Lastly, there was also reduction of nuclear and 
cytoplasmic Gli1 in cancer cells, suggesting reduced Hedgehog signalling in cancer cells 29 
(Figure 6E, Supplementary Figure 14). The alteration of the vascular and immune sub-
compartments of stroma, as shown by us before14, 30, could also lead to enhanced necrosis 
in tumours in vivo, especially with combination treatment, ultimately resulting in tumour 
shrinkage.   
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Discussion 
 The effective reduced growth of the tumour size with a combination of stromal and 
cancer cell co-targeting is clinically relevant, since many locally advanced and borderline 
resectable cancers may be rendered surgically resectable using this regimen, a hypothesis 
which is now ready to be tested in clinical trials. The findings reported here are in sharp 
contrast to two recent studies exploring more radical approaches involving complete stromal 
ablation 8, 9 suggesting that stromal “normalisation” is much preferable over stromal ablation 
approaches 10. Rhim et al, recently demonstrated that ablating sonic hedgehog-dependent 
stroma resulted in a more vascular tumour with poor differentiation, which, in part, could be 
abrogated by VEGF signalling blockade 8. In a parallel approach, Ozdemir et al, by 
genetically ablating alpha-SMA-positive stroma, demonstrated presence of more invasive 
tumours, characterized with hypoxia, an epithelial-to-mesenchymal transition and alterations 
in immune surveillance. Specifically, this resulted in increased CD4+Foxp3+ T-regulatory cell 
infiltration, leading to a more aggressive tumour phenotype 8, 9. In contrast, our findings 
suggest that restoring homeostatic stromal characteristics, rather than stromal ablation, have 
tumour-suppressive rather than a tumour-enhancing effect. This may be, in part, due to the 
homeostatic role of naturally occurring vitamin A analogue, and, in part, due to the 
pleiotropic actions of ATRA which are of relevance to pancreatic embryology and 
development. 
 Indeed, it has been demonstrated that ATRA influences multiple signalling cascades 
through selective retinoid receptor signalling (retinoid versus rexinoid receptors and isoforms 
of both subsets such as α,β,γ) in embryonic pancreas development, injury and regeneration 
13, 31-34. In particular, ATRA has a predominant effect on acinar morphology rather than 
endocrine cells, due to the epithelial-mesenchymal interactions in the developing pancreas 
34. Retinoic acid is critical for the developing pancreas, where it can interact with, and 
influence Wnt, TGFβ (transforming growth factor β), BMP (bone morphogenetic protein), and 
other signalling cascades 35, all of which are understood to be hijacked and altered by 
cancer cells to recruit stromal cells 36. Previously we had demonstrated that restoring the 
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quiescent nature of PSC using ATRA can alter the signalling flux within the tumour-stroma 13 
as well as intra-stromal cross-talk 14 of key pathways relevant to pancreatic cancer 
progression.  
 The enhanced apoptosis and reduction in proliferation of cancer cells, seen in this 
report, may result from reduction of canonical Wnt signalling in the tumour compartment, as 
a result of modification in the stromal compartment, by sequestering Wnt ligands, due to 
sFRP4 secretion 13. Furthermore the disrupted fibroblast growth factor (FGF) signalling in the 
stromal compartment 17, or targeting of other signalling cascades such as Hedgehog, IL6, 
CXCL12 amongst others 14, could detrimentally effect the cancer cells by altering the 
signalling flux of, rather than selectively ablating, key cascades. FGF2/FGFR1 nuclear 
translocation is vital to activation of PSC which is required for cancer progression, as 
recently shown by us 17. Other modifications in extra-cellular matrix deposition and re-
modelling such as Collagen and Fibronectin can affect  the cyto-protective micro-
environment of cancer cells 37, internalisation and re-cycling of key integrins 18 and 
migration/invasion of cancer cells 38 as well as immune cells 14. 
 This alteration of a number of signalling pathways, in turn, may affect key epithelial 
cellular processes such apico-basal polarity 25, matrix re-modelling 18, epithelial-
mesenchymal transition 26 and, thus, halt cancer progression. Therefore, multiple tumour-
stroma cross-talk signalling cascades affecting numerous cancer and stellate cell processes 
are altered by ATRA when administered in clinically achievable dosing schedule.  
 Moreover, the alteration of immune cell infiltrate, vascularity and hypoxia 
demonstrated by us previously 13, 14, 30 in relation to stromal targeting therapy is relevant to 
this combination treatment. We demonstrate, here, that chemotherapy is more effective 
when combined with ATRA in altering intra-stromal or peri-tumoural cross-talk in the tissue 
micro-environment, particularly the enhancement of vascularity and the consequent 
reduction in hypoxia. In fact, it has been long understood that the tumour micro-environment 
exerts a protective influence on the cancer cells through multiple mechanisms such as 
resistance to alkylating agents 39, direct cell-cell contact between cancer and stromal cells 40, 
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through many signalling cascades, thus enhancing the tumour cell autonomous resistance to 
chemotherapy. We were unable to detect enhanced levels of active metabolite of 
Gemcitabine, and we speculate this may be related to increased necrotic component of the 
tumour which will not contain active metabolite. In addition, the consistency of the results 
obtained from these two different PDAC models (one in vitro, one in vivo) suggests that the 
organotypic models may be useful preclinical tools for dissection of the molecular signalling 
pathways involved in PDAC drug resistance. Modulating the 3D OT cultures would recapture 
important aspects of the tumour microenvironment that can influence cancer cell behaviour. 
 Thus, based on data presented here, we postulate that the effect of this combination 
strategy of co-targeting cancer and stromal cells is more likely to involve dampening of a 
multitude of signalling cascades, rather than via a single, specific pathway or mechanism 
and, therefore, altering a number of key cellular processes. This notion concurs with 
separate attempts to restore homeostatic capability of desmoplastic stroma by targeting the 
vitamin D receptor 15, as well as normalisation of vascularisation with dual-action 
combination therapy 30. Given the known fat-soluble vitamin deficiency in patients with 
PDAC, due to biliary and pancreatic duct obstruction, the proposal to restore homeostatic 
stromal function, in conjunction with cancer targeting with conventional chemotherapy, 
appears to be a viable therapeutic opportunity underpinned by the clinical features of this 
cancer. This hypothesis, thus, has enough rationale to be explored in a human clinical trial 
involving patients with PDAC.  
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Figure Legends 
 
Figure 1. Effect on cancer cells proliferation and apoptosis after combination 
treatment with Gemcitabine and ATRA.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for OT resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10-30 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P< 0.01, * P<0.05. PSC: Pancreatic stellate cell. 
Cancer cell proliferation index in organotypics (A,B) and KPC mice (C).  
Cancer cell apoptotic index in organotypics (D,E) and KPC mice (F). 
Please see Supplementary Figure 3 for representative images.  
 
  
Figure 2. Effect on cancer and stellate cells invasion after combination treatment with 
Gemcitabine and ATRA. 
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for OT resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P<0.01, * P<0.05. PCC: Pancreatic cancer cell; PSC: Pancreatic stellate cell. 
Cancer cell invasion index in organotypics (A,B).  
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Stellate cell invasion index in an organotypic model (C, D)  
Stellate cell density in KPC mice (E).  Stellate cell density in KPC was determined as green 
signal pixel intensity per area; the number of stellate cells was not counted as it was not 
possible to identify accurately this cell type in the KPC tumour section.  
Please see Supplementary Figure 4 for representative images.  
 
  
Figure 3. Effect on pancreatic stellate cell activity, vascularity and hypoxia after 
combination treatment with Gemcitabine and ATRA.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for organotypics resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10-30 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P< 0.01, * P<0.05. PSC: Pancreatic stellate cell. 
Stellate cell activity in terms of fibronectin deposition in an organotypic model (A,B) and KPC 
mice (C) and, in terms of Collagen I deposition in the KPC mouse model (D).  
Vascular density as determined by Endomucin stain in the KPC mouse model (E). Hypoxic 
index as determined by GLUT-1 stain (F). 
Please see Supplementary Figures 5 and 6 for representative images. 
 
 
Figure 4. Effect of combination treatment with Gemcitabine and ATRA on tumour 
growth, Gemcitabine and ATRA intra-tumoural levels in KPC mice.  
(A) Percentage necrotic area as determined by H&E slides. Summary data from LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice (KPC mice) treated with either vehicle, 
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Gemcitabine alone, ATRA alone or a combination of Gemcitabine with ATRA as shown by 
median and inter-quartile range as box and whisker (min-max) plots. 5-6 mice per group 
were enrolled. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc 
analysis. *** P<.001, ** P< 0.01, * P<0.05. See Supplementary Figure 6C for representative 
images. 
(B) Percentage change in tumour volume between pre-treatment (Day -2) and post-
treatment (Day 7) was measured by ultrasound in the KPC mice model.  
(C) Serum and pancreatic tumour ATRA concentration demonstrated correlation in mice 
receiving ATRA treatment (Pearson’s correlation coefficient 0.66 (95% CI 0.09-0.9)). A 
regression line and it’s 95% confidence intervals are shown.  
(D)  ATRA tumour tissue concentration in KPC mice treated with ATRA or Gem/ATRA  
(E) Tumour tissue gemcitabine metabolites in Gem and Gem/ATRA treated mice.  
ns: not significant. 
  
 
Figure 5: The combination of Gemcitabine with ATRA affects multiple embryonic 
signalling cascades in cancer cells and stroma in organotypic cultures and KPC mice.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 
Sections from three experimental replicates were carried out for organotypics resulting in 18 
high power field measurements. Three mice per group were selected to allow assessments 
in 10 high power fields per section. Comparisons were made by Kruskal-Wallis test followed 
by Dunn’s post-hoc analysis. *** P<0.001, * P<0.05. 
FGF2 nuclear expression index in organotypics and KPC mice (A-C).  
FGFR1 nuclear expression index in organotypics and KPC mice (D-F).  
RARβ nuclear expression index in KPC mice (G).  
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sFRP4 stromal expression index in KPC mice (H).  
Please see supplementary figures 7, 8 and 9 for representative images. 
 
 
Figure 6: The combination of Gemcitabine with ATRA affects apical polarity, 
epithelial-mesenchymal transition and hedgehog signalling in cancer cells within 
organotypic cultures and KPC mice.  
Representative images from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre mice (KPC mice), as indicated, treated with either vehicle, 
Gemcitabine alone, ATRA alone or the combination of Gemcitabine with ATRA. Bold 
arrowheads used to indicate positive stain and other arrowheads to indicate negative stain. 
A) Capan-1 cells stained with an anti-cytokeratin antibody (green) and anti-β-catenin (red) 
antibody was used to localize the presence of β-catenin in organotypic cultures. Cytokeratin 
positive cancer cells demonstrate loss of nuclear β-catenin in ATRA treated organotypic 
cultures. Please see Supplementary Figure 10 for detailed data on KPC mice and 
organotypic cultures. Scale bar 10µm. 
B) Anti-cytokeratin antibody (green) and anti-Ezrin antibody (red) were used to localize the 
presence of Ezrin in KPC mice. Cytokeratin positive cancer cells demonstrate loss of 
membranous Ezrin in ATRA treated murine tissues. Please see Supplementary Figure 11 for 
detailed data on KPC mice and organotypic cultures.  
C) Anti-cytokeratin antibody (green) and anti-Twist1 (red) antibody were used to localize the 
presence of Twist1 in Capan1/PS1 organotypic cultures. Cytokeratin-positive cancer cells 
demonstrate loss of nuclear Twist1 in ATRA organotypic cultures. Cytokeratin negative PSC 
demonstrate nuclear Twist1 to act as an internal positive control. Please see Supplementary 
Figure 12 for detailed data on KPC mice and organotypic cultures.  
D) Anti-Zeb1 antibody (green) and anti-E-cadherin (red) antibody were used to localize the 
presence of Zeb1 in Capan1/PS1 organotypic cultures. E-cadherin-positive cancer cells 
demonstrate loss of nuclear Zeb1 in ATRA organotypic cultures. E-cadherin negative PSC 
Page 21 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Carapuça et al  Stroma and cancer co-targeting 
22 
 
demonstrate nuclear Zeb1 to act as an internal positive control. Please see Supplementary 
Figure 13 for detailed data on KPC mice and organotypic cultures.  
E) In KPC mice, anti-Gli1 staining (brown) was used to localize Gli1 expression. Loss of 
Nuclear Gli1 in epithelial appearing cells was demonstrable within ATRA treated murine 
PDAC tissues. Please see Supplementary Figure 14 for detailed data on KPC mice.  
Scale bar 10µm. 
 
 
Page 22 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Effect on cancer cells proliferation and apoptosis after combination treatment with Gemcitabine and ATRA  
275x397mm (300 x 300 DPI)  
 
 
Page 23 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Effect on cancer and stellate cells invasion after combination treatment with Gemcitabine and ATRA  
275x397mm (300 x 300 DPI)  
 
 
Page 24 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Effect on pancreatic stellate cell activity, vascularity and hypoxia after combination treatment with 
Gemcitabine and ATRA  
275x397mm (300 x 300 DPI)  
 
 
Page 25 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Effect of combination treatment with Gemcitabine and ATRA on tumour growth, Gemcitabine and ATRA 
intra-tumoural levels in KPC mice  
275x397mm (300 x 300 DPI)  
 
 
Page 26 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
The combination of Gemcitabine with ATRA affects multiple embryonic signalling cascades in cancer cells and 
stroma in organotypic cultures and KPC mice  
275x397mm (300 x 300 DPI)  
 
 
Page 27 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
The combination of Gemcitabine with ATRA affects apical polarity, epithelial-mesenchymal transition and 
hedgehog signalling in cancer cells within organotypic cultures and KPC mice  
190x275mm (300 x 300 DPI)  
 
 
Page 28 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Carapuça et al  Stroma and cancer co-targeting 
1 
 
Anti-stromal treatment together with chemotherapy targets multiple signalling 
pathways in pancreatic adenocarcinoma.  
 
Elisabete F. Carapuça1#, Emilios Gemenetzidis1#, Christine Feig2, Tashinga E. Bapiro2, 
Michael D. Williams2, Abigail S. Wilson1, Francesca R. Delvecchio1, Prabhu Arumugam1, 
Richard P. Grose1, Nicholas R Lemoine3, Frances M. Richards2, Hemant M Kocher1,4*  
 
1Centres for Tumour Biology and 3Molecular Oncology, Barts Cancer Institute – a CRUK 
Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UK.  
2The University of Cambridge Cancer Research-UK Cambridge Institute, Li Ka Shing Centre, 
Robinson Way Cambridge, CB2 0RE, England. 
4Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, 
London, E1 1BB, UK. 
 
Running title: stroma and cancer co-targeting  
 
*Corresponding author: Hemant M Kocher MS MD FRCS, Queen Mary University of 
London, Centre for Tumour Biology, Barts Cancer Institute – a CRUK Centre of Excellence, 
Charterhouse Square, London EC1M 6BQ, UK.  
Tel: +44(0) 20 7882 3579; Email: h.kocher@qmul.ac.uk  
#Contributed equally 
Page 29 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Carapuça et al  Stroma and cancer co-targeting 
2 
 
Supplementary Figure 1: Design of experiments and determination of dosing 
schedule. 
A) Determination of Gemcitabine GI50 (Cytotoxic effect: growth inhibition of 50%) alone, or in 
combination with ATRA (1µM), on AsPC1 (blue and black lines) or Capan1 (green and red 
lines) cell growth. Pancreatic cancer cell lines AsPC-1 and Capan1 in 2D monoculture were 
exposed once, to different concentrations of Gemcitabine, and were allowed to grow for a 
period of up to seven days, prior to assessing proliferation rates. The GI50 for Gemcitabine 
was determined as 240nM for AsPC1, and 48nM for Capan1, indicating that AsPC1 cells are 
more resistant to Gemcitabine, when compared to Capan1 cell line. Addition of daily ATRA, 
to this treatment regimen had no effect on the GI50 curves of either cell line, indicating the 
lack of any combinational effect of ATRA with Gemcitabine in 2D monocultures on cancer 
cells.  
B) Determination of Gemcitabine GI50 alone or in combination with ATRA (1µM) on 
pancreatic stellate cells (PSC) growth. PSC showed sensitivity to Gemcitabine (GI50 26nM), 
which increased when treatment was combined with daily ATRA exposure. At least, in 2D 
cultures, the actively proliferating PSC appear to be sensitive to Gemcitabine. 
C) i) Treatment protocol of the 3D organotypic cultures with Gemcitabine weekly for two 
consecutive weeks, mimicking treatment currently in use in the clinic (1). Representative 
images of H&E stained sections of gels resultant from AsPC1 (ii) or Capan1 (iii) organotypic 
cultures, treated with Gemcitabine at various doses in order to determine Gemcitabine GI50 
(concentration that reduces epithelial cell layer thickness by 50%). Gemcitabine GI50 was 
slightly higher at 300nM for AsPC1 and 100nM for Capan1 organotypic cultures than in the 
2D monocultures. The increased value of GI50 is anticipated due to cyto-protective effect of 
organized 3D matrix particularly Collagen I (2). Intriguingly PSC layer thickness was 
unaffected by Gemcitabine treatment, when PSC and cancer cells were combined (data not 
shown).  
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D) Representative image of a section of an organotypic culture treated with BrdU (red) and 
stained with a cytokeratin antibody (green) to delineate cancer cells. Representative graph of 
the percentage of cancer and stellate cells with BrdU incorporation. To determine the rates 
of nucleoside uptake in organotypic cultures, BrdU pulse chase was carried out. BrdU is an 
analogue of the nucleoside thymidine, and Gemcitabine an analogue of cytidine. BrdU was 
administered at the same concentrations that Gemcitabine would be added to the 3D co-
culture models. The percentage of incorporation of BrdU by PSC was much less than by 
tumour cells, which confirms that Gemcitabine has minimal cytotoxic effect on PSC in 
organotypic culture model. This effect may be due to a slower proliferation rate of PSC. 
Thus, they do not incorporate the nucleoside analogue at the same rate as cancer cells. 
Therefore, the cytotoxic effect of Gemcitabine is largely specific to the epithelial cancer cells. 
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Supplementary Figure 2: The combination treatment of Gemcitabine with ATRA does 
not affect PSC number, and consequently gel length and thickness is also 
unchanged.  
A) Schematic representation of an organotypic culture of admixed cancer cells and PSC, 
seeded on top of gel composed of Matrigel and Collagen I that mimics the tumour ECM 
environment. Measurements of cancer cell layer thickness, gel length, gel thickness are 
schematically represented and have been previously described (3).  
B, C) Cancer cell layer thickness was unaffected in presence of PSC in Capan1/PS1 (B) and 
AsPC1/PS1 (C) organotypic cultures, respectively, upon treatment with vehicle, Gemcitabine 
alone, ATRA alone or a combination of Gemcitabine and ATRA.  
D,E) Total PSC number was also unaffected in Capan1/PS1 (D) and AsPC1/PS1 (E) 
organotypic  cultures respectively upon treatment.  
F,G) Gel thickness was also unaffected in Capan1/PS1 (F) and AsPC1/PS1 (G) organotypic 
cultures, respectively, upon treatment.  
H,I) Gel length was also unaffected in Capan1/PS1 (H) and AsPC1/PS1 (I) organotypic 
cultures, respectively, upon treatment.  
9-15 experimental replicates were carried out for organotypic cultures. Comparisons were 
made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
ns: not significant 
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Supplementary Figure 3: The combination of Gemcitabine with ATRA affects cancer 
cell proliferation, apoptosis in organotypic cultures, as well as in KPC mice.  
A) Representative images from organotypic cultures (OT) treated with either vehicle, 
Gemcitabine alone, ATRA alone or the combination of Gemcitabine with ATRA. Capan1 
cells stained with an anti-cytokeratin antibody (green) and proliferating Capan1 cells stained 
with an anti-Ki67 antibody (red) to determine ratio of proliferating cancer cells per field. 
B) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with vehicle, Gemcitabine, ATRA or Gemcitabine with ATRA, 
and stained with an anti-CK8 antibody (red) and proliferating cancer cells stained with an 
anti-Ki67 antibody (green) to determine the ratio of proliferating cancer cells per field.  
C) Representative images from organotypic cultures (OT) after same treatment regimen, 
where Stellate cells were stained with an anti-alpha-SMA antibody in green and with an anti-
Ki67 antibody (red) to determine ratio of proliferating stellate cells per field. 
D) Representative images of organotypic gel sections where Capan1 cells were stained by 
immuno-histochemistry with an anti-cleaved caspase-3 antibody. Apoptotic cancer cells 
were identified by the cytoplasmic brown staining. There was no staining within the PSC 
layer. Percentage apoptotic cancer cells (based on morphology) were determined.  
E) Representative images of tumour sections from KPC mice stained with an anti-cleaved 
caspase-3 antibody to determine apoptotic cells. There was no staining in non-epithelial 
compartment. Percentage apoptotic cancer cells (based on morphology) were determined. 
F) Representative images of tumour sections from KPC mice stained by 
immunofluorescence with an anti-alpha-SMA antibody and with an anti-cleaved caspase-3 
antibody to determine the ratio of apoptotic stellate cells. There was no staining in the 
stromal compartment.  
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Supplementary Figure 4: The combination of Gemcitabine with ATRA affects cancer 
and stellate cell invasion in organotypic cultures as well as stellate cells density in 
KPC mice.  
A) Representative images of organotypic gel sections where Capan1 cells were stained with 
a cytokeratin antibody (green) and PSC were stained with an anti-αSMA antibody (red) to 
identify the cells that have invaded the gel. The yellow line marks the junction between the 
PSC layer and the extracellular matrix (top of the gel). The number of invading cells was 
counted directly on the section on the Axioplan microscope, to accurately identify the top of 
the gel and identify the cell type and number that invaded into the gel.  
B) i and ii) Representative H&E stained image from a Capan-1/PS1 OT section that clearly 
shows the cancer cell layer, the gel and the top of the gel where the stellate cell layer is 
demonstrable. The dashed black line in ii) marks the top of the gel. Invading cells were 
counted below the black line..  
C) Representative images of tumour sections from KPC mice stained with an anti-αSMA  
antibody (green) to identify PSC. Stromal cell density was determined by green pixel 
intensity. Pericytes were accounted for as described in Figure 6A. Scale bar 100 µm (except 
C where Scale bar = 50 µm). 
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Supplementary Figure 5: ATRA alters stellate cells activation status.  
A) Representative images of organotypic sections where Capan1 cells were stained with an 
anti-Cytokeratin antibody (green) and extra-cellular matrix (ECM) deposition by an anti-
Fibronectin antibody (red). Note: the ECM gel formed at inception with Collagen I and 
Matrigel contains no fibronectin. Hence, fibronectin shown here represents ECM generated 
by cells co-cultured in 3D. Fibronectin deposition was only present around PSC, indicating 
PSC were source of this ECM protein. Fibronectin deposition was normalized to PSC 
number to determine PSC activity as shown in Supplementary Figure 2. Scale bar 100 µm. 
B) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
mice (KPC mice) stained by immuno-histochemistry with anti-Fibronectin antibody. 
Fibronectin expression was scored based on intensity and degree of brown staining as 
described before (4). Scale bar 50 µm. 
C) Representative images of Collagen deposition in KPC mice tumour sections stained with 
Picrosirius Red. Pixel intensity was determined as described before (5). Scale bar 100 µm. 
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Supplementary Figure 6: The combination treatment of Gemcitabine with ATRA alters 
the vascular density, hypoxic environment and the necrosis pattern in murine 
tumours.  
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
mice (KPC mice) stained with an anti-Endomucin antibody (red) to identify blood vessels and 
an anti-αSMA antibody (green) to identify stellate cells as well as pericytes. The number of 
blood vessels increased in the tumour/stromal area of PDAC tumours of mice treated with 
ATRA or with the combination Gemcitabine /ATRA, while at the same time there is a 
reduction of αSMA expression (after subtracting doubly stained structures to exclude 
pericytes). Scale bar 100 µm. 
B) Representative images KPC mice tumour sections stained with an anti-GLUT1 antibody 
(green) to mark hypoxic areas in the tumours. Pixel intensity determined level of hypoxia as 
described before (6). Scale bar 100 µm.  
C) Representative images of H&E stained tumour sections from mice. Necrotic areas, 
identified by morphology, are marked by the dotted lines in black. Percentage of necrotic 
area was determined based on total surface area of tumour. Scale bar 5000 µm. 
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Supplementary Figure 7: ATRA treatment affects pancreatic stellate cell activity by 
reducing the nuclear translocation FGF2. 
A-D) Representative images of sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice 
(KPC mice) stained with an anti-FGF2 antibody (red) and an anti-Cytokeratin antibody 
(green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice. There is a clear reduction of nuclear FGF2 expression in stromal 
cells (Cytokeratin –ve cells) from mice treated with ATRA. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear FGF2 expressing stromal cells and empty arrowheads pointing to stromal 
cells not expressing FGF2 in the nucleus.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the difference of nuclear FGF2 expression in stellate cells 
upon treatment with ATRA. Scale bar 10 µm. 
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Supplementary Figure 8: ATRA treatment affects the pancreatic stellate cell activity by 
reducing the nuclear translocation of FGFR1. 
A-D) Representative images of sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice 
(KPC mice) stained with an anti-FGFR1 antibody (red) and an anti-αSMA antibody (green) to 
identify stromal cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice. There is a clear reduction of nuclear FGFR1 expression in stromal 
αSMA-positive cells in the mice treated with ATRA. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear FGFR1 expressing stromal cells and empty arrowheads pointing to 
stromal cells with no nuclear FGFR1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the difference of nuclear FGFR1 expression in stellate cells 
upon treatment with ATRA which is in concordance with FGF2 expression pattern seen in 
Supplementary figure 8. Scale bar 10 µm. 
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Supplementary Figure 9: Nuclear RARβ expression in, and stromal sFRP4 secretion 
by, pancreatic stellate cells is altered upon treatment with ATRA alone and in 
combination with Gemcitabine.  
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained by immuno-histochemistry with an anti-RARβ antibody. 
Nuclear RARβ expression is most enhanced in stellate cells of sections from mice treated 
with ATRA. Zoom in images show the amplification of the marked areas of main images, 
which show the nuclear RARβ expression in stetalle cells of sections from ATRA treated 
mice in comparison to Vehicle or Gemcitabine alone treated mice. Scale bar 100 µm. Zoom 
in images: Scale bar 10 µm. 
B) Representative images of tumour sections from KPC mice stained by immuno-
histochemistry with an anti-sFRP4 antibody. Stromal sFRP4 expression is most enhanced in 
tumour surrounding environment of sections from mice treated with ATRA alone or in 
combination with Gemcitabine. Scale bar 50 µm. Zoom in images show a significant 
expression of sFRP4 in the stroma of tumour from ATRA or ATRA/Gemcitabine combination 
treated mice in comparison to Vehicle or Gemcitabine alone treated mice. Zoom in images: 
Scale bar 10 µm. 
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Supplementary Figure 10: ATRA disrupts Wnt-β-catenin signalling pathway. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-β-catenin antibody (red) and an anti-Cytokeratin 
antibody (green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear β-catenin expression in epithelial cells and empty arrowheads pointing to 
no nuclear β-catenin expression.  
e-h) Zoom in images of marked areas of OT main images (E-H) also with bold and empty 
arrowheads pointing to the differences of nuclear β-catenin expression in epithelial cells. 
There is a shift of the spatial β-catenin localization that spans from the cell nuclei, in 
epithelial cell either from KPC tumours or OT cultures treated with vehicle or Gemcitabine 
alone to the cell membrane upon treatment with ATRA or Gemcitabine and ATRA. Scale bar 
10 µm. 
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Supplementary Figure 11: The combination treatment affects the lumen formation and 
apico-basal polarity of cancer cells. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Ezrin antibody (red) and an anti-Cytokeratin 
antibody (green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm. 
 a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to Ezrin cell membrane expression in cancer cells and empty arrowheads pointing 
to loss of membranous Ezrin expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences in Ezrin expression in cancer cells. Ezrin 
expression is reduced in cancer cells of KPC mice tumours or OT cultures, after the 
combination treatment (Gemcitabine with ATRA). Scale bar 10 µm. 
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Supplementary Figure 12: ATRA alone or in combination with Gemcitabine nuclear 
Twist1 expression within cancer cells.  
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Twist1 antibody (red) and an anti-Cytokeratin 
antibody (green).  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear Twist1 expression in epithelial cells expression and empty arrowheads 
pointing to loss of this nuclear Twist1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences of nuclear Twist1 expression in epithelial cells 
upon different treatment conditions. ATRA alone or in combination with Gemcitabine reduces 
nuclear Twist1 expression in epithelial cells, whilst in stellate cells nuclear Twist1 expression 
remains unaltered. Scale bar 10 µm. 
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Supplementary Figure 13: The combination treatment affects the nuclear 
translocation of transcription factor ZEB1 in cancer cells. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Zeb1 antibody (red) and an anti-αSMA antibody 
(green).  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with an anti-
E-cadherin antibody (red) and an anti-Zeb1 antibody (green). Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear Zeb1 expression within epithelial cells and empty arrowheads pointing to 
loss of nuclear Zeb1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences of nuclear Zeb1 expression in epithelial cells 
upon different treatment conditions. ATRA in combination with Gemcitabine reduces nuclear 
Zeb1 expression in epithelial cells, whilst in stellate cells nuclear Zeb1 expression remains 
unaltered. Scale bar 10 µm. 
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Supplementary Figure 14: The combination treatment affects the Hedgehog signalling 
in cancer cells. 
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained by immuno-histochemistry with an anti-Gli1 antibody. Zoom in 
images show the clear expression of nuclear and cytoplasmic Gli1 in ductal cells sections 
from untreated or Gemcitabine treated mice in comparison to a reduction of Gli1 expression 
in cancer cells of ATRA/Gemcitabine treated mice.  
B) Representative images of OT sections stained by immuno-histochemistry with an anti-
Gli1 antibody. Zoom in images clearly show the reduction in Gli expression of cancer cells 
from Gemcitabine/ATRA treated OT cultures, which is in agreement with the differences in 
Gli1 expression also observed in KPC mice.  Scale bar 100 µm. Zoom in images: Scale bar 
10 µm. 
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Supplementary table 1: KPC mice characteristics at recruitment  
Treatment type Age (days) Tumour volume (mm3 on 2 days before 
treatment  as measured by ultrasound) 
Control 249 137.761 
Control 188 303.706 
Control 170 326.367 
Control 117 163.306 
Control 120 195.04 
Control 128 149.467 
Gemcitabine 211 124.714 
Gemcitabine 200 274.747 
Gemcitabine 189 232.725 
Gemcitabine 177 284.779 
Gemcitabine 176 149.722 
Gemcitabine 102 191.824 
ATRA 216 156.138 
ATRA 177 302.217 
ATRA 243 327.712 
ATRA 223 211.803 
ATRA 150 160.042 
ATRA + Gemcitabine 119 324.267 
ATRA + Gemcitabine 171 234.933 
ATRA + Gemcitabine 185 263.636 
ATRA + Gemcitabine 218 495.181 
ATRA + Gemcitabine 204 239.703 
ATRA + Gemcitabine 124 343.271 
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Supplementary table 2: Table of antibodies  
Sections 
species 
origin 
Antibody 
Catalogue 
reference 
Incubation 
period 
Antigen 
retrieval 
method 
IF (or IHC) 
dilution 
Organotypic 
sections 
(anti-human) 
Rabbit Cytokeratin DAKO Z0662 1h, RT HIER 1:200 
Mouse Fibronectin SIGMA F0916 ON, 40C Pepsin 1:100 
Mouse Ki67 DAKO M7240 1h, RT HIER 1:100 
Mouse αSMA DAKO M0851 1h, RT HIER 1:300 
Rabbit CC3 
Cell signaling 
D175 
1h, RT HIER 1:400 (IHC) 
Rabbit Gli1* 
Chemicon 
AB3444 
1h, RT 
HIER 1:300 (IHC) 
Mouse E-Cadherin Abcam ab1416 ON, 40C HIER 
1:100 
Rabbit RAR-β* Abcam ab53161 1h, RT 
HIER 1:200 (IHC) 
Mouse Twist1* Abcam ab50887 ON, 40C HIER 
1:100 
Rabbit Zeb1* 
Santa cruz sc-
25388 
ON, 40C HIER 
1:500 
Mouse FGF2* Millipore 05-118 
ON, 40C HIER 
1:100 
Rabbit FGFR1* Abcam ab10646 
ON, 40C HIER 
1:500 
Rabbit SFRP4* 
Santa cruz sc-
30152 
1h, RT 
N.A. 1:50 (IHC) 
Mouse Ezrin* BD 10603 
ON, 40C HIER 
1:200 
Mouse β-Catenin* BD 610154 
ON, 40C HIER 
1:200 
KPC mouse 
sections 
(anti-mouse) 
Rabbit CK8 Abcam ab59400 ON, 40C or 
1h, RT 
HIER 1:100 
Rabbit Fibronectin  Abcam ab23750 1h, RT HIER 1:200 (IHC) 
Rabbit Ki67 Abcam ab15580 1h, RT HIER  1:150 
Mouse αSMA  SIGMA F3777 ON, 40C HIER 1:500 
Rabbit CC3 Cell signaling 1h, RT HIER 1:400 (IHC) 
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D175 
Rat Endomucin Santa Cruz Sc-
65495 
1h, RT HIER 1:100 
Rabbit Glut1 Millipore 07-1401 ON, 40C HIER 1:250 
ON: overnight; 1h: one hour, RT; room temperature; 
HIER: Heat Induced Epitope Retrieval (citrate buffer pH6) 
N.A.: not applicable  
*: used also in mouse 
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Abstract 
Background & Aims: Stromal targeting for pancreatic ductal adenocarcinoma (PDAC) is 
rapidly becoming an attractive option, due to lack of efficacy of standard chemotherapy and 
increased knowledge about PDAC stroma. We postulated that combining stromal therapy 
may enhance anti-tumour efficacy of chemotherapy. 
Methods: Gemcitabine and all-trans retinoic acid (ATRA) were combined in a clinically 
applicable regimen, to target cancer cells and pancreatic stellate cells (PSC) respectively, in 
3D organotypic culture models and genetically engineered mice (LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre mice: KPC mice) representing the spectrum of PDAC. 
Results: In two distinct sets of organotypic models as well as KPC mice, we demonstrate a 
reduction in cancer cell proliferation and invasion together with enhanced cancer cell 
apoptosis when ATRA is combined with Gemcitabine compared to vehicle or either agent 
alone. Simultaneously, PSC activity :  (in the form of deposition of extra-cellular matrix 
proteins such as Collagen and Fibronectin), and PSC invasive ability were both diminished 
in response to combination therapy. These actions were mediated by affecting a range of 
signalling cascades (Wnt, hedgehog, retinoid and FGF were studied) in cancer as well as 
stellate cells, effecting myriad epithelial cellular functions such as epithelial-mesenchymal 
transition, cellular polarity and lumen formation. At the tissue level, this resulted in enhanced 
tumour necrosis, increased vascularity, and diminished hypoxia. Consequently, there was an 
overall reduction in tumour size.  
Conclusions: Stromal co-targeting (ATRA) alongside chemotherapy (Gemcitabine) is a 
potential clinical strategy. Experimental evidence suggests that the effect of this combination 
is mediated by dampening multiple signalling cascades in the tumour-stroma cross-talk, 
rather than ablating stroma or targeting a single pathway.  
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Introduction 
 Combination chemotherapy regimens consisting of oxaliplatin, irinotecan, 
fluorouracil, and leucovorin (FOLFIRINOX) 1 or nab-Paclitaxel with Gemcitabine 2 have 
resulted in increased median overall survival compared to Gemcitabine alone, which is the 
currently approved and widely used palliative mono-therapy 3. However, gains have been 
marginal, and this may well be because desmoplasia remains largely unaltered with 
therapy4. 
 PDAC is characterised by a pronounced desmoplastic stroma mediated by the 
activation of quiescent pancreatic stellate cells (PSC) 5. This stroma creates a uniquely 
hypoxic microenvironment that, paradoxically, promotes both tumour growth and metastatic 
spread while inducing vascular collapse, thus creating a barrier to the perfusion/diffusion of 
therapeutic agents6; which, altogether, makes this cellular desmoplastic stroma an appealing 
therapeutic target. The pharmacologic inhibition of the sonic hedgehog signalling pathway in 
combination with Gemcitabine, in a genetically engineered mouse model, LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice, produced variable results dependent on 
disease stage 7, 8, yet demonstrated proof-of-concept that stromal targeting was feasible. 
However, stromal ablation leads to a biologically more aggressive form of PDAC 8, 9, 
indicating that attention to the spatio-temporal aspects4 of the tumour-stroma cross-talk is 
critical for its effective targeting 10. 
 PSC play a central role in desmoplastic stroma 11, 12. Previously, we demonstrated 
that restoring the quiescent state of PSC, by replenishing their physiological retinol depots 
using the pleiotropic agent: all-trans retinoic acid (ATRA), halted tumour progression through 
targeting multiple dynamic tumour-stromal signalling cascades 13, 14; a notion recently 
supported by targeting Vitamin D receptor 15. In this report, we used combination therapy to 
target pancreatic cancer cells and their supporting stroma in in vitro and in vivo PDAC 
models to demonstrate efficacy of this strategy. It is feasible to target and normalize multiple 
altered signalling cascades mediating tumour-stroma cross-talk with this approach. 
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Methods 
Organotypic cultures: 
 Short tandem repeat (STR) profiled cancer (Capan1, AsPC1) and stellate (PS1) cells 
were cultured, and pancreatic organotypic cultures were constructed as described elsewhere 
11, 16-18. Two cancer cell lines were utilised in organotypic models representing a spectrum of 
PDAC differentiation11, 13, 18. The pancreatic stellate cell line used was PS1, which was 
obtained from an unused normal pancreas (rejected for transplantation) donated by the UK 
human tissue bank (Ethics approval; Trent MREC (/MRE04/)). The cells were isolated in the 
laboratory, using the outgrowth method 19, 20 followed by immortalisation by expression of 
ectopic human telomerase reverse transcriptase (hTERT) 21, and verified as being of stellate 
cell origin by positive immunostaining for Desmin, Vimentin, αSMA and GFAP and ability to 
store Vitamin A 13.  
 In contrast to previous reports 13, 17, we allowed the cancer-stellate interaction to be 
established for 10 days 11, before commencing therapeutic dosing, for the treatment of an 
established tumour analogue. The cancer cell: st llate cell ratio was 1:2, as determined 
previously, providing the most aggressive, invasive phenotype within this model which 
mimicked histological features of advanced human cancer 11. Multiple biological and 
technical replicates performed by two independent researchers ensured reproducibility. 
Treatment was given for two cycles, as per the human clinical protocol 3, 22, as summarized 
in Supplementary Figure 1. Briefly, treatment of organotypic cultures was performed daily 
with ATRA (Sigma R2625, St. Louis, MO, USA) at 1µM or with weekly Gemcitabine (2’, 2’-
difluoro 2’-deoxycytidine, dFdC) (Eli Lilly, Indianapolis, IN, USA) at 100 nM (Capan-1/PS1) or 
400 nM (AsPC1/PS1), or with the combination of Gemcitabine/ATRA or with respective 
vehicles. Organotypic cultures were harvested on day 24, fixed in 10% neutral buffered 
formalin (Cell Pathology BAF-001003A, Newton, UK), embedded in paraffin and cut into 4 
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µm sections. Each experiment had three technical replicates and at least three biologic 
repeats.  
 
KPC mice treatment 
 All animal work was done in accordance with the UK Animals (Scientific Procedures) 
Act 1986, revised by the Amendment Regulations 2012 (SI 2012/3039) to transpose 
European Directive 2010/63/EU with approval from the local Animal Welfare and Ethical 
Review Body, and following the 2010 guidelines from the United Kingdom Coordinating 
Committee on Cancer Research 23. Compound mutant KPC mice with mature, established 
tumours were enrolled at a median age of 180 days and used as described previously 7, 13. 
ATRA was dissolved to 25mg/ml in dimethyl sulfoxide, further diluted to 2.98mg/ml in (2-
Hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich H5784) and finally to 1.5mg/ml with sterile 
filtered tap water. This ATRA solution was administered orally to mice at 15 mg/kg daily for 
seven days 13. Gemcitabine was injected intraperitoneally at 100 mg/kg on days zero, three 
and seven 7. The volume of the tumours was measured by ultrasound two days before the 
beginning of the treatment, and mice bearing tumour volume of ~250 mm3 (Supplementary 
Figure 1 Table 1) were selected for the study. Tumours were harvested seven days after 
beginning of the treatment, and immediately submerged in formalin for 24 hours, followed by 
embedding in paraffin blocks for further sectioning and immunostaining analysis. The 
primary endpoint of study was drug efficacy as measured by a number of surrogate markers. 
Samples of tumours and serum were also snap-frozen for analysis of drug concentrations 
using LC-MS/MS. 
 
Immunostaining  
 Paraffin-embedded sections were dewaxed and re-hydrated, and antigens were 
retrieved and immunostained for a range of markers to study cellular attributes using a range 
of antibodies (Supplementary Table 2) as described before 13, 16.  
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Quantification  
 The quantification of all cell counts and intensity of staining in the organotypic 
sections was performed on four-six representative pictures per organotypic gel of which 
there were three technical replicates for each of the biological repeats (minimum three). For 
the KPC mice, either the total tumour area or at least ten representative pictures per total 
tumour area were scanned using either Axioplan microscope (Zeiss 40 V 4.8.10, Carl Zeiss 
MicroImaging LLC, New York, US), confocal laser scanning microscope LSM 510 (Carl 
Zeiss MicroImaging LLC, New York, US) or Pannoramic 250 High Throughput 
Scanner  (3DHISTECH Ltd., Budapest, Hungary). The intensities of fluorescence in the 
green/red channels were normalised with IgG controls and background fluorescence and 
calculated in an unbiased, blinded manner using either Adobe Photoshop CS6 (San Jose, 
CA USA), or Pannoramic Viewer Software (3DHISTECH Ltd., Budapest, Hungary), and 
Image J software (NIH, Maryland USA) as described before 13. The methods for 
measurement of gel length and thickness, cancer and stellate total cell number per gel are 
described elsewhere 11. 
 
Tissue Gemcitabine and ATRA levels 
 Tissue samples were homogenized in 50% acetonitrile:water at a concentration of 
100 mg/mL using a precellys homogenizer.  An aliquot of the homogenate was precipitated 
with acetonitrile containing a stable isotope (5 deuterium) label internal standard of ATRA. 
Measurement was carried out against a calibration line prepared in mouse plasma 
homogenate (100 mg/mL) in 50% acetonitrile:water. The MS/MS used was a Sciex 
4000Qtrap equipped with a heated nebulizer atmospheric pressure chemical ionization 
source operating in the negative mode at 350ºC. MRM transitions were 301-205 and 306-
205 for unlabeled and labeled ATRA respectively. LC was performed using a Dionex 
Ultimate 3000 LC and autosampler, using a gradient separation on a Phenomenex Kinetex 
2.6 µm, 150x2.1 mm column. The binary gradient was run at 0.2 ml/min, starting at 40:60 
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A:B changing to 10:90 A:B from 0-15mins then holding from 15-17.6 minutes before quickly 
ramping back to 40:60 A:B at 17.62 minutes. The LC-MS/MS system was controlled by 
Analyst 1.4 software. In order to ensure the correct isomer (ATRA) was measured a system 
suitability test was run at the beginning and end of the sample analysis to demonstrate 
separation of the ATRA isomer from the 9- and 13-cis isomers of retinoic acid (data not 
shown). (Supplementary Figure 7).  
 Fresh frozen tumour and plasma samples were processed and analysed for 
Gemcitabine and its metabolites by LC-MS/MS as previously described 24. Briefly, LC-
MS/MS  was performed on a TSQ Vantage triple stage quadrupole mass spectrometer 
(Thermo Scientific, USA) fitted with a heated electrospray ionization (HESI-II) probe 
operated in positive and negative mode at a spray voltage of 2.5 KV, capillary temperature of 
150ºC. Quantitative data acquisition was done using LC Quan2.5.6 (Thermo Fisher 
Scientific, USA).  
 
Statistical analysis 
 Statistical analysis and graphical data representation were performed using the 
software PRISM V.6 (Graphpad, La Jolla, USA). Summary data are expressed as the 
median with interquartile range since the distribution was non-Gaussian. Comparisons were 
performed using Kruskal-Wallis test with Dunn’s multiple comparison test. The level of 
significance was set at P < 0.05.  
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Results  
 Dosing schedule and timing for treatment of organotypic cultures and KPC mice with 
Gemcitabine and ATRA were designed to mimic clinically relevant treatment regimens for 
advanced human pancreatic cancer based on previously available data 3, 7, 11, 13, 22. In vitro 
optimisations such as growth inhibition to 50% of control (GI50) levels for Gemcitabine were 
determined for translation into the organotypic 3D model.and summarized in 
Supplementary Figure 1.. Interestingly, we found the presence of extra-cellular matrix 
(ECM) protein in 3D model to have preferential cytoprotective effect on the pancreatic 
stellate cells (PSC). This resulted in different GI50 for both PSC and cancer cells in 3D 
models compared to 2D culture (Supplementary Figures 1A-C, data not shown). Previously 
we had demonstrated ATRA had no direct effect on cancer cells by performing PSC or 
cancer cell alone organotypic cultures 13. 
 Mice were enrolled independently and randomly allocated into the trial at 
advanced stage based on ultrasound (Supplementary Table 1 7). We then sought to 
identify effects on the cancer cells and stellate cells separately within this experimental 
design mimicking advanced PDAC. Results are presented across all biological 
replicates using a fold change for various attributes measured as summarized in 
Supplementary Figures 2 and 3. There was no change in gel contractility in organotypic 
cultures with any of the agents as compared to vehicle treatment (Supplementary Figure 2 
and 3). 
 There was a significant reduction in proliferation of cancer cells induced by the 
presence of ATRA either alone or in combination with Gemcitabine in vivo as well as in vitro, 
across all experimental conditions (Figures 1A-C, Supplementary Figures 43A 4B and B).No 
significant difference was noted for stellate cells proliferation after any of the treatments 
(Supplementary Figure 3C). However, induction of apoptosis was more pronounced with 
introduction of ATRA in the combination arm, suggesting that Gemcitabine potentiates the 
effect of ATRA (Figures 1D-F, Supplementary Figure 4C3D and E). We did not find any 
significant difference in the apoptotic index of stellate cells after any of the treatments, in 
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both PDAC models (Supplementary Figure 3F). Cancer cell invasion into the extra-cellular 
matrix, a surrogate marker for metastatic capability, was also reduced by the combination 
treatment (Figures 2A-B, Supplementary Figure 4A-B). 
 PSC invasion into the ECM, and stellate cell density in mouse tumours, were 
reduced by ATRA treatment alone, and in combination with Gemcitabine (Figures 2C-E, 
Supplementary Figures 4A-C). PSC numbers within organotypic gels did not change, 
reflecting the protective effect of matrix proteins on PSC in 3D, not seen in 2D in vitro state 
(Supplementary Figures 1B and 2D-E). However, the PSC activation state was altered by 
ATRA and the combination of Gemcitabine and ATRA, as indicated by a significant reduction 
in deposition of extra-cellular matrix (ECM) substrates such as Fibronectin and Collagen I, 
implying stromal re-modelling (Figures 3A-D, Supplementary Figures 5A-C). 
 Together with stromal re-modelling, we demonstrated increased vascularity of the 
KPC tumours, associated with decreasing hypoxia (Figures 3E, 3F, Supplementary Figures 
6A, 6B). Surprisingly, despite this reduction in hypoxia, there was increased necrosis, in 
vivo, with combination treatment (Figure 4A)., Supplementary Figure 6C). This resulted in 
smaller tumours in mice treated with combination therapy (Figure 4B). Certainly, with this 
regimen, both agents can be delivered successfully in vivo into the tumour parenchyma as 
measured by LC-MS/MS (Figures 4C-E). Furthermore, the tissue ATRA (not 9-cis and 13-cis 
RA) is directly correlated to serum ATRA measurements allowing surrogate measurements 
to be easily and readily performed (Figure 4C, Supplementary Figures 7C, 7D). 
 The precise mechanism(s) underpinning the success of this combination therapy are 
difficult to pinpoint, since ATRA influences multiple signalling cascades 13. The enhanced 
apoptosis and reduction in proliferation of cancer cells may result from the reduction of Wnt 
signalling in the tumour compartment 13, disrupted fibroblast growth factor (FGF) signalling in 
the stromal compartment 17, or targeting of other signalling cascades such as Hedgehog, 
IL6, and CXCL12 amongst others 14.  
 In our experimental models, we could demonstrate a reduction in nuclear 
translocation of FGF2 and FGFR1 in PSC upon treatment of KPC mice and organotypic 
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cultures with ATRA (Figures 5A-F, Supplementary Figures 7,8); this co-translocation being 
pertinent to PSC activity as demonstrated before 13. There was enhanced nuclear Retinoic 
Acid Receptor β (RARβ) visibility within the PSC in KPC tumours upon treatment with ATRA 
treatment (Figure 5G, Supplementary Figure 9A), which is known to reflect PSC quiescence 
13. Upregulation of PSC RARβ activity enhances secretion of secreted Frizzled related 
protein 4 (sFRP4) from the quiescent PSC as demonstrated before 13. We could 
demonstrate increased stromal sFRP4 upon treatment with ATRA (Figure 5H, 
Supplementary Figure 9B). This modulation within PSC upon treatment with ATRA, in turn, 
led to reduced nuclear β-catenin, which is normally trans-located translocates to the 
nucleus following canonical Wnt signalling activation 13, 25 (Figure 6A, Supplementary Figure 
10). sFRP4 can sequester Wnt ligands within stroma to abrogate canonical Wnt signalling 
flux, and also act as gatekeeper, and, thus, affect epithelial-mesenchymal transition (EMT), 
apoptosis and invasion within cancer cells 26, 27.  
 In addition, there was reduction in Ezrin expression (Figure 6B, Supplementary 
Figure 11), which has previously been shown to enhance podosomal rosette formation 25. 
Ezrin is also a marker for lumen formation and apico-basal polarity and such changes could 
be observed in the organotypic cultures more clearly than KPC mice but were difficult to 
quantify (data not shown). Furthermore, there was suppression in the expression of EMT 
activating transcription factors, as evidenced by reduction of nuclear Twist1 and Zeb1 in 
PDAC cells (Figures 6C and D, Supplementary Figures 12, 13), which may be related to 
reduction of canonical Wnt signalling 28. Lastly, there was also reduction of nuclear and 
cytoplasmic Gli1 in cancer cells, suggesting reduced Hedgehog signalling in cancer cells 29 
(Figure 6E, Supplementary Figure 14). The alteration of the vascular and immune sub-
compartments of stroma, as shown by us before14, 30, could also lead to enhanced necrosis 
in tumours in vivo, especially with combination treatment, ultimately resulting in tumour 
shrinkage.   
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Discussion 
 The effective reduction of reduced growth of the tumour size with a combination of 
stromal and cancer cell co-targeting is clinically relevant, since many locally advanced and 
borderline resectable cancers may be rendered surgically resectable using this regimen, a 
hypothesis which is now ready to be tested in clinical trials. The findings reported here are in 
sharp contrast to two recent studies exploring more radical approaches involving complete 
stromal ablation 8, 9 suggesting that stromal “normalisation” is much preferable over stromal 
ablation approaches 10. Rhim et al, recently demonstrated that ablating sonic hedgehog-
dependent stroma resulted in a more vascular tumour with poor differentiation, which, in 
part, could be abrogated by VEGF signalling blockade 8. In a parallel approach, Ozdemir et 
al, by genetically ablating alpha-SMA-positive stroma, demonstrated presence of more 
invasive tumours, characterized with hypoxia, an epithelial-to-mesenchymal transition and 
alterations in immune surveillance. Specifically, this resulted in increased CD4+Foxp3+ T-
regulatory cell infiltration, leading to a more aggressive tumour phenotype 8, 9. In contrast, 
our findings suggest that restoring homeostatic stromal characteristics, rather than stromal 
ablation, have tumour-suppressive rather than a tumour-enhancing effect. This may be, in 
part, due to the homeostatic role of naturally occurring vitamin A analogue, and, in part, due 
to the pleiotropic actions of ATRA which are of relevance to pancreatic embryology and 
development. 
 Indeed, it has been demonstrated that ATRA influences multiple signalling cascades 
through selective retinoid receptor signalling (retinoid versus rexinoid receptors and isoforms 
of both subsets such as α,β,γ) in embryonic pancreas development, injury and regeneration 
13, 31-34. In particular, ATRA has a predominant effect on acinar morphology rather than 
endocrine cells, due to the epithelial-mesenchymal interactions in the developing pancreas 
34. Retinoic acid is critical for the developing pancreas, where it can interact with, and 
influence Wnt, TGFβ (transforming growth factor β), BMP (bone morphogenetic protein), and 
other signalling cascades 35, all of which are understood to be hijacked and altered by 
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cancer cells to recruit stromal cells 36. Previously we had demonstrated that restoring the 
quiescent nature of PSC using ATRA can alter the signalling flux within the tumour-stroma 13 
as well as intra-stromal cross-talk 14 of key pathways relevant to pancreatic cancer 
progression.  
 The enhanced apoptosis and reduction in proliferation of cancer cells, seen in this 
report, may result from reduction of canonical Wnt signalling in the tumour compartment, as 
a result of modification in the stromal compartment, by sequestering Wnt ligands, due to 
sFRP4 secretion 13. Furthermore the disrupted fibroblast growth factor (FGF) signalling in the 
stromal compartment 17, or targeting of other signalling cascades such as Hedgehog, IL6, 
CXCL12 amongst others 14, could detrimentally effect the cancer cells by altering the 
signalling flux of, rather than selectively ablating, key cascades. FGF2/FGFR1 nuclear 
translocation is vital to activation of PSC which is required for cancer progression, as 
recently shown by us 17. CXCL12 signalling is vital in recruiting immune cells within the 
cancer micro-environment. Other modifications in extra-cellular matrix deposition and re-
modeling modelling such as Collagen and Fibronectin can affect  the cyto-protective micro-
environment of cancer cells 37, internalisation and re-cycling of key integrins 18 and 
migration/invasion of cancer cells 38 as well as immune cells 14. 
 This alteration of a number of signalling pathways, in turn, may affect key epithelial 
cellular processes such apico-basal polarity 25, matrix re-modelling 18, epithelial-
mesenchymal transition 26 and, thus, halt cancer progression. Therefore, multiple tumour-
stroma cross-talk signalling cascades affecting numerous cancer and stellate cell processes 
are altered by ATRA when administered in clinically achievable dosing schedule.  
 Moreover, the alteration of immune cell infiltrate, vascularity and hypoxia 
demonstrated by us previously 13, 14, 30 in relation to stromal targeting therapy is relevant to 
this combination treatment. We demonstrate, here, that chemotherapy is more effective 
when combined with ATRA in altering intra-stromal or peri-tumoural cross-talk in the tissue 
micro-environment, particularly the enhancement of vascularity and the consequent 
reduction in hypoxia. In fact, it has been long understood that the tumour micro-environment 
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exerts a protective influence on the cancer cells through multiple mechanisms such as 
resistance to alkylating agents 39, direct cell-cell contact between cancer and stromal cells 40, 
through many signalling cascades, thus enhancing the tumour cell autonomous resistance to 
chemotherapy. We were unable to detect enhanced levels of active metabolite of 
Gemcitabine, and we speculate this may be related to increased necrotic component of the 
tumour which will not contain active metabolite. In addition, the consistency of the results 
obtained from these two different PDAC models (one in vitro, one in vivo) suggests that the 
organotypic models may be useful preclinical tools for dissection of the molecular signalling 
pathways involved in PDAC drug resistance. Modulating the 3D OT cultures would recapture 
important aspects of the tumour microenvironment that can influence cancer cell behaviour. 
 Thus, based on data presented here, we postulate that the effect of this combination 
strategy of co-targeting cancer and stromal cells is more likely to involve dampening of a 
multitude of signalling cascades, rather than via a single, specific pathway or mechanism 
and, therefore, altering a number of key cellular processes. This notion agrees concurs with 
separate attempts to restore homeostatic capability of desmoplastic stroma by targeting the 
vitamin D receptor 15, as well as normalisation of vascularisation with dual-action 
combination therapy 30. Given the known fat-soluble vitamin deficiency in patients with 
PDAC, due to biliary and pancreatic duct obstruction, the proposal to restore homeostatic 
stromal function, in conjunction with cancer targeting with conventional chemotherapy, 
appears to be a viable therapeutic opportunity underpinned by the clinical features of this 
cancer. This hypothesis, thus, has enough rationale to be explored in a human clinical trial 
involving patients with PDAC.  
.  
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Figure Legends 
 
Figure 1. Effect on cancer cells proliferation and apoptosis after combination 
treatment with Gemcitabine and ATRA.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for OT resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10-30 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P< 0.01, * P<0.05. PSC: Pancreatic stellate cell. 
Cancer cell proliferation index in organotypics (A,B) and KPC mice (C).  
Cancer cell apoptotic index in organotypics (D,E) and KPC mice (F). 
Please see Supplementary Figure 2 for an example of method of calculation and 
Supplementary Figure 43 for representative images respectively.  
 
  
Figure 2. Effect on cancer and stellate cells invasion after combination treatment with 
Gemcitabine and ATRA. 
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for OT resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P<0.01, * P<0.05. PCC: Pancreatic cancer cell; PSC: Pancreatic stellate cell. 
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Cancer cell invasion index in organotypics (A,B).  
Stellate cell invasion index in an organotypic model (C, D)  
Stellate cell density in KPC mice (E).  Stellate cell density in KPC was determined as green 
signal pixel intensity per area; the number of stellate cells was not counted as it was not 
possible to identify accurately this cell type in the KPC tumour section.  
Please see Supplementary Figure 2 for an example of method of calculation and 4 for 
representative images respectively.  
 
  
Figure 3. Effect on pancreatic stellate cell activity, vascularity and hypoxia after 
combination treatment with Gemcitabine and ATRA.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 9-15 
experimental replicates were carried out for organotypics resulting in 35-50 high power field 
measurements. 5-6 mice per group were enrolled to allow assessments in 10-30 high power 
fields. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
*** P<0.001, ** P< 0.01, * P<0.05. PSC: Pancreatic stellate cell. 
Stellate cell activity in terms of fibronectin deposition in an organotypic model (A,B) and KPC 
mice (C) and, in terms of Collagen I deposition in the KPC mouse model (D).  
Vascular density as determined by Endomucin stain in the KPC mouse model (E). Hypoxic 
index as determined by GLUT-1 stain (F). 
Please see Supplementary Figures 2, 5 and 6 for method of calculation and for 
representative images respectively. 
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Figure 4. Effect of combination treatment with Gemcitabine and ATRA on tumour 
growth, Gemcitabine and ATRA intra-tumoural levels in KPC mice.  
(A) Percentage necrotic area as determined by H&E slides. Summary data from LSL-
KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice (KPC mice) treated with either vehicle, 
Gemcitabine alone, ATRA alone or a combination of Gemcitabine with ATRA as shown by 
median and inter-quartile range as box and whisker (min-max) plots. 5-6 mice per group 
were enrolled. Comparisons were made by Kruskal-Wallis test followed by Dunn’s post-hoc 
analysis. *** P<.001, ** P< 0.01, * P<0.05. See Supplementary Figure 6C for representative 
images. 
(B) Percentage change in tumour volume between pre-treatment (Day -2) and post-
treatment (Day 7) was measured by ultrasound in the KPC mouse model.  
(C) Serum and pancreatic tumour ATRA concentration demonstrated correlation in mice 
receiving ATRA treatment (Pearson’s correlation coefficient 0.66 (95% CI 0.09-0.9)). A 
regression line and it’s 95% confidence intervals are shown.  
(D)  ATRA tumour tissue concentration in KPC mice treated with ATRA or Gem/ATRA  
(E) Tumour Tissue Gemcitabine metabolites in Gem and Gem/ATRA treated mice.  
Please see Supplementary Figure 7 for methods of measurement.  
ns: not significant. 
 
  
Figure 5: The combination of Gemcitabine with ATRA affects multiple embryonic 
signalling cascades in cancer cells and stroma in organotypic cultures and KPC mice.  
Summary data from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) treated with either vehicle, Gemcitabine alone, ATRA alone or a 
combination of Gemcitabine with ATRA as shown by median and interquartile range as box 
and whisker (min-max) plots. All observations were normalized to controls (vehicle). 
Sections from three experimental replicates were carried out for organotypics resulting in 18 
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high power field measurements. Three mice per group were selected to allow assessments 
in 10 high power fields per section. Comparisons were made by Kruskal-Wallis test followed 
by Dunn’s post-hoc analysis. *** P<0.001, * P<0.05. 
FGF2 nuclear expression index in organotypics and KPC mice (A-C).  
FGFR1 nuclear expression index in organotypics and KPC mice (D-F).  
RARβ nuclear expression index in KPC mice (G).  
sFRP4 stromal expression index in KPC mice (H).  
Please see supplementary figures 7, 8 and 9 for representative images. 
 
 
Figure 6: The combination of Gemcitabine with ATRA affects apical polarity, 
epithelial-mesenchymal transition and hedgehog signalling in cancer cells within 
organotypic cultures and KPC mice.  
Representative images from organotypic cultures (OT) and LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre mice (KPC mice), as indicated, treated with either vehicle, 
Gemcitabine alone, ATRA alone or the combination of Gemcitabine with ATRA. Bold 
arrowheads used to indicate positive stain and other arrowheads to indicate negative stain. 
A) Capan-1 cells stained with an anti-cytokeratin antibody (green) and anti-β-catenin (red) 
antibody was used to localize the presence of β-catenin in organotypic cultures. Cytokeratin 
positive cancer cells demonstrate loss of nuclear β-catenin in ATRA treated organotypic 
cultures. Please see Supplementary Figure 10 for detailed data on KPC mice and 
organotypic cultures. Scale bar 10µm. 
B) Anti-cytokeratin antibody (green) and anti-Ezrin antibody (red) were used to localize the 
presence of Ezrin in KPC mice. Cytokeratin positive cancer cells demonstrate loss of 
membranous Ezrin in ATRA treated murine tissues. Please see Supplementary Figure 11 for 
detailed data on KPC mice and organotypic cultures.  
C) Anti-cytokeratin antibody (green) and anti-Twist1 (red) antibody were used to localize the 
presence of Twist1 in Capan1/PS1 organotypic cultures. Cytokeratin-positive cancer cells 
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demonstrate loss of nuclear Twist1 in ATRA organotypic cultures. Cytokeratin negative PSC 
demonstrate nuclear Twist1 to act as an internal positive control. Please see Supplementary 
Figure 12 for detailed data on KPC mice and organotypic cultures.  
D) Anti-Zeb1 antibody (green) and anti-E-cadherin (red) antibody were used to localize the 
presence of Zeb1 in Capan1/PS1 organotypic cultures. E-cadherin-positive cancer cells 
demonstrate loss of nuclear Zeb1 in ATRA organotypic cultures. E-cadherin negative PSC 
demonstrate nuclear Zeb1 to act as an internal positive control. Please see Supplementary 
Figure 13 for detailed data on KPC mice and organotypic cultures.  
E) In KPC mice, anti-Gli1 staining (brown) was used to localize Gli1 expression. Loss of 
Nuclear Gli1 in epithelial appearing cells was demonstrable within ATRA treated murine 
PDAC tissues. Please see Supplementary Figure 14 for detailed data on KPC mice.  
Scale bar 10µm. 
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Supplementary Figure 1: Design of experiments and determination of dosing 
schedule. 
A) Determination of Gemcitabine GI50 (Cytotoxic effect: growth inhibition of 50%) alone, or in 
combination with ATRA (1µM), on AsPC1 (blue and black lines) or Capan1 (green and red 
lines) cell growth. Pancreatic cancer cell lines AsPC-1 and Capan1 in 2D monoculture were 
exposed once, to different concentrations of Gemcitabine, and were allowed to grow for a 
period of up to seven days, prior to assessing proliferation rates. The GI50 for Gemcitabine 
was determined as 240nM for AsPC1, and 48nM for Capan1, indicating that AsPC1 cells are 
more resistant to Gemcitabine, when compared to Capan1 cell line. Addition of daily ATRA, 
to this treatment regimen had no effect on the GI50 curves of either cell line, indicating the 
lack of any combinational effect of ATRA with Gemcitabine in 2D monocultures on cancer 
cells.  
B) Determination of Gemcitabine GI50 alone or in combination with ATRA (1µM) on 
pancreatic stellate cells (PSC) growth. PSC showed sensitivity to Gemcitabine (GI50 26nM), 
which increased when treatment was combined with daily ATRA exposure. At least, in 2D 
cultures, the actively proliferating PSC appear to be sensitive to Gemcitabine. 
C) i) Treatment protocol of the 3D organotypic cultures with Gemcitabine weekly for two 
consecutive weeks, mimicking treatment currently in use in the clinic (1). Representative 
images of H&E stained sections of gels resultant from AsPC1 (ii) or Capan1 (iii) organotypic 
cultures, treated with Gemcitabine at various doses in order to determine Gemcitabine GI50 
(concentration that reduces epithelial cell layer thickness by 50%). Gemcitabine GI50 was 
slightly higher at 300nM for AsPC1 and 100nM for Capan1 organotypic cultures than in the 
2D monocultures. The increased value of GI50 is anticipated due to cyto-protective effect of 
organized 3D matrix particularly Collagen I (2). Intriguingly PSC layer thickness was 
unaffected by Gemcitabine treatment, when PSC and cancer cells were combined (data not 
shown).  
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D) Representative image of a section of an organotypic culture treated with BrdU (red) and 
stained with a cytokeratin antibody (green) to delineate cancer cells. Representative graph of 
the percentage of cancer and stellate cells with BrdU incorporation. To determine the rates 
of nucleoside uptake in organotypic cultures, BrdU pulse chase was carried out. BrdU is an 
analogue of the nucleoside thymidine, and Gemcitabine an analogue of cytidine. BrdU was 
administered at the same concentrations that Gemcitabine would be added to the 3D co-
culture models. The percentage of incorporation of BrdU by PSC was much less than by 
tumour cells, which confirms that Gemcitabine has minimal cytotoxic effect on PSC in 
organotypic culture model. This effect may be due to a slower proliferation rate of PSC. 
Thus, they do not incorporate the nucleoside analogue at the same rate as cancer cells. 
Therefore, the cytotoxic effect of Gemcitabine is largely specific to the epithelial cancer cells. 
D) Design of organotypic treatment regimen: i) Previously, in order to dissect this cell-
specific targeting, organotypic cultures were treated with ATRA (1µM) for a period of 10 days 
(3). However, this model/schedule lacked features of advanced pancreatic cancer (4). ii) 
Hence, we allowed epithelial-stellate cell interaction to be established for ten days before 
commencing treatment. Organotypic cultures were treated with either Gemcitabine once 
weekly, mimicking the regimen treatment being currently being given to patients in the 
clinic(1), or ATRA daily, again using a clinically relevant protocol (5), or with the combination 
of both or their respective vehicles.  
E) KPC mice treatment scheme: Compound mutant KPC mice with mature, established 
tumours were enrolled at a median age of 180 days and used as described previously (3, 6). 
Mice were treated with Gemcitabine at 100 mg/Kg by intraperitoneal injection on a Q3Dx4 
schedule, and with ATRA daily at 15 mg/Kg by oral gavage, or the combination of both at the 
appropriate times. The volume of the tumours was measured by ultrasound two days before 
the beginning of the treatment, and mice bearing tumour volume of an average 250 mm3 
were selected for the study. . 
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Supplementary Figure 2: Determination of marker expression fold-change.  
A) i) Representative image of a Photoshop screen-shot of an organotypic section, stained 
with a anti-cytokeratin antibody (green) to identify cancer cells and with an anti-Fibronectin 
(FN) antibody (red) to identify FN expression by PSC. The window tool selects the colour 
range of the marker (FN) under study.  
ii) Pre-specified colour range attributes were loaded from one common .AXT colour range 
file to ensure equal pixel detection across samples (shown now in a black & white channel). 
This would assess the pixel number that will represent the marker expression intensity, in 
this case FN.  
iii) Representative histogram indicating the pixel number detected accordingly with the 
colour range selected.  
B) i) Graphic representation of the number of pixels from FN expression per field of a gel, 
in a total of three gels for one biological repeat, across all treatment conditions. At least four 
images per gel were analysed for the quantification of fibronectin.  
ii) Graphic representation of the median number of pixels from FN expression as 
summarized per gel.  
C) i) Representative image of an Image J screenshot of the same organotypic section as in 
Ai), and of the window tool used to quantify the stellate cell number based on the nuclei 
morphology, size and absence of cytokeratin stain.  
ii) Representative graph of FN pixel number normalized to total PSC number (FN index) per 
gel, in a total of three gels from one biological experiment, for each arm of treatment.   
D) Graphic representation of FN index from three biological experiments, as shown in (Bii) 
for one single biological experiment. This summary graph would represent one graph in the 
Main Figure for each attribute investigated. 
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Supplementary Figure 2: The combination treatment of Gemcitabine with ATRA does 
not affect PSC number, and consequently gel length and thickness is also 
unchanged.  
A) Schematic representation of an organotypic culture of admixed cancer cells and PSC, 
seeded on top of gel composed of Matrigel and Collagen I that mimics the tumour ECM 
environment. Measurements of cancer cell layer thickness, gel length, gel thickness are 
schematically represented and have been previously described (3).  
B, C) Cancer cell layer thickness was unaffected in presence of PSC in Capan1/PS1 (B) and 
AsPC1/PS1 (C) organotypic cultures, respectively, upon treatment with vehicle, Gemcitabine 
alone, ATRA alone or a combination of Gemcitabine and ATRA.  
D,E) Total PSC number was also unaffected in Capan1/PS1 (D) and AsPC1/PS1 (E) 
organotypic  cultures respectively upon treatment.  
F,G) Gel thickness was also unaffected in Capan1/PS1 (F) and AsPC1/PS1 (G) organotypic 
cultures, respectively, upon treatment.  
H,I) Gel length was also unaffected in Capan1/PS1 (H) and AsPC1/PS1 (I) organotypic 
cultures, respectively, upon treatment.  
9-15 experimental replicates were carried out for organotypic cultures. Comparisons were 
made by Kruskal-Wallis test followed by Dunn’s post-hoc analysis. 
ns: not significant 
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Supplementary Figure 3: The combination of Gemcitabine with ATRA affects cancer 
cell proliferation, apoptosis and invasion in organotypic cultures, as well as cancer 
cell proliferation and apoptosis in KPC mice.  
A) Representative images from organotypic cultures (OT) treated with either vehicle, 
Gemcitabine alone, ATRA alone or the combination of Gemcitabine with ATRA. Capan1 
cells stained with an anti-cytokeratin antibody (green) and proliferating Capan1 cells stained 
with an anti-Ki67 antibody (red) to determine ratio of proliferating cancer cells per field. 
B) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
mice (KPC mice) treated with vehicle, Gemcitabine, ATRA or Gemcitabine with ATRA, and 
stained with an anti-CK8 antibody (red) and proliferating cancer cells stained with an anti-
Ki67 antibody (green) to determine the ratio of proliferating cancer cells per field.  
C) Representative images from organotypic cultures (OT) after same treatment regimen, 
where Stellate cells were stained with an anti-alpha-SMA antibody in green and with an anti-
Ki67 antibody (red) to determine ratio of proliferating stellate cells per field. 
 
D) Representative images of organotypic gel sections where Capan1 cells were stained by 
immuno-histochemistry with an anti-cleaved caspase-3 antibody. Apoptotic cancer cells 
were identified by the cytoplasmic brown staining. There was no staining within the PSC 
layer. Percentage apoptotic cancer cells (based on morphology) were determined.  
E) Representative images of tumour sections from KPC mice stained with an anti-cleaved 
caspase-3 antibody to determine apoptotic cells. There was no staining in non-epithelial 
compartment. Percentage apoptotic cancer cells (based on morphology) were determined. 
F) Representative images of tumour sections from KPC mice stained by 
immunofluorescence with an anti-alpha-SMA antibody and with an anti-cleaved caspase-3 
antibody to determine the ratio of apoptotic stellate cells. There was no staining in the 
stromal compartment.  
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Supplementary Figure 4: The combination of Gemcitabine with ATRA affects cancer 
and stellate cell invasion in organotypic cultures as well as stellate cells density in 
KPC mice.  
A) Representative images of organotypic gel sections where Capan1 cells were stained with 
a cytokeratin antibody (green) and PSC were stained with an anti-αSMA antibody (red) to 
identify the cells that have invaded the gel. The yellow line marks the junction between the 
PSC layer and the extracellular matrix (top of the gel). The number of invading cells was 
counted directly on the section on the Axioplan microscope, to accurately identify the top of 
the gel and identify the cell type and number that invaded into the gel.  
B) i and ii) Representative H&E stained image from a Capan-1/PS1 OT section that clearly 
shows the cancer cell layer, the gel and the top of the gel where the stellate cell layer is 
demonstrable. The dashed black line in ii) marks the top of the gel. Invading cells were 
counted below the black line..  
C) Representative images of tumour sections from KPC mice stained with an anti-αSMA  
antibody (green) to identify PSC. Stromal cell density was determined by green pixel 
intensity. Pericytes were accounted for as described in Figure 6A. Scale bar 100 µm (except 
C where Scale bar = 50 µm). 
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Supplementary Figure 5: ATRA alters stellate cells activation status.  
A) Representative images of organotypic sections where Capan1 cells were stained with an 
anti-Cytokeratin antibody (green) and extra-cellular matrix (ECM) deposition by an anti-
Fibronectin antibody (red). Note: the ECM gel formed at inception with Collagen I and 
Matrigel contains no fibronectin. Hence, fibronectin shown here represents ECM generated 
by cells co-cultured in 3D. Fibronectin deposition was only present around PSC, indicating 
PSC were source of this ECM protein. Fibronectin deposition was normalized to PSC 
number to determine PSC activity as shown in Supplementary Figure 2. Scale bar 100 µm. 
B) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
mice (KPC mice) stained by immuno-histochemistry with anti-Fibronectin antibody. 
Fibronectin expression was scored based on intensity and degree of brown staining as 
described before (4). Scale bar 50 µm. 
C) Representative images of Collagen deposition in KPC mice tumour sections stained with 
Picrosirius Red. Pixel intensity was determined as described before (5). Scale bar 100 µm. 
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Supplementary Figure 6: The combination treatment of Gemcitabine with ATRA alters 
the vascular density, hypoxic environment and the necrosis pattern in murine 
tumours.  
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre 
mice (KPC mice) stained with an anti-Endomucin antibody (red) to identify blood vessels and 
an anti-αSMA antibody (green) to identify stellate cells as well as pericytes. The number of 
blood vessels increased in the tumour/stromal area of PDAC tumours of mice treated with 
ATRA or with the combination Gemcitabine /ATRA, while at the same time there is a 
reduction of αSMA expression (after subtracting doubly stained structures to exclude 
pericytes). Scale bar 100 µm. 
B) Representative images KPC mice tumour sections stained with an anti-GLUT1 antibody 
(green) to mark hypoxic areas in the tumours. Pixel intensity determined level of hypoxia as 
described before (6). Scale bar 100 µm.  
C) Representative images of H&E stained tumour sections from mice. Necrotic areas, 
identified by morphology, are marked by the dotted lines in black. Percentage of necrotic 
area was determined based on total surface area of tumour. Scale bar 5000 µm. 
 
Supplementary Figure 7: Determination of murine tumour volume and tumour and 
serum concentration of ATRA and Gemcitabine with its metabolites.  
A) Representative image of ultrasound measurements and formula used to determine 
tumour volume at various time-points.  
B) Enrolment volume of the murine tumours. There is no significant difference of volume 
amongst the tumours. Comparisons were made by Kruskal-Wallis test followed by Dunn’s 
post-hoc analysis. 
C) Chromatogram system suitability test for ability to separate ATRA from 9-cis and 13-cis 
isomers of retinoic acid. 
D) Chromatogram of Plasma Extract from Mouse 8362. 
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Supplementary Figure 7: ATRA treatment affects pancreatic stellate cell activity by 
reducing the nuclear translocation FGF2. 
A-D) Representative images of sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice 
(KPC mice) stained with an anti-FGF2 antibody (red) and an anti-Cytokeratin antibody 
(green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice. There is a clear reduction of nuclear FGF2 expression in stromal 
cells (Cytokeratin –ve cells) from mice treated with ATRA. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear FGF2 expressing stromal cells and empty arrowheads pointing to stromal 
cells not expressing FGF2 in the nucleus.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the difference of nuclear FGF2 expression in stellate cells 
upon treatment with ATRA. Scale bar 10 µm. 
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Supplementary Figure 8: ATRA treatment affects the pancreatic stellate cell activity by 
reducing the nuclear translocation of FGFR1. 
A-D) Representative images of sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre mice 
(KPC mice) stained with an anti-FGFR1 antibody (red) and an anti-αSMA antibody (green) to 
identify stromal cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice. There is a clear reduction of nuclear FGFR1 expression in stromal 
αSMA-positive cells in the mice treated with ATRA. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear FGFR1 expressing stromal cells and empty arrowheads pointing to 
stromal cells with no nuclear FGFR1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the difference of nuclear FGFR1 expression in stellate cells 
upon treatment with ATRA which is in concordance with FGF2 expression pattern seen in 
Supplementary figure 8. Scale bar 10 µm. 
 
Page 95 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Carapuça et al  Stroma and cancer co-targeting 
12 
 
Supplementary Figure 9: Nuclear RARβ expression in, and stromal sFRP4 secretion 
by, pancreatic stellate cells is altered upon treatment with ATRA alone and in 
combination with Gemcitabine.  
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained by immuno-histochemistry with an anti-RARβ antibody. 
Nuclear RARβ expression is most enhanced in stellate cells of sections from mice treated 
with ATRA. Zoom in images show the amplification of the marked areas of main images, 
which show the nuclear RARβ expression in stetalle cells of sections from ATRA treated 
mice in comparison to Vehicle or Gemcitabine alone treated mice. Scale bar 100 µm. Zoom 
in images: Scale bar 10 µm. 
B) Representative images of tumour sections from KPC mice stained by immuno-
histochemistry with an anti-sFRP4 antibody. Stromal sFRP4 expression is most enhanced in 
tumour surrounding environment of sections from mice treated with ATRA alone or in 
combination with Gemcitabine. Scale bar 50 µm. Zoom in images show a significant 
expression of sFRP4 in the stroma of tumour from ATRA or ATRA/Gemcitabine combination 
treated mice in comparison to Vehicle or Gemcitabine alone treated mice. Zoom in images: 
Scale bar 10 µm. 
 
Page 96 of 113
http://mc.manuscriptcentral.com/jpath
The Journal of Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Carapuça et al  Stroma and cancer co-targeting 
13 
 
Supplementary Figure 10: ATRA disrupts Wnt-β-catenin signalling pathway. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-β-catenin antibody (red) and an anti-Cytokeratin 
antibody (green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear β-catenin expression in epithelial cells and empty arrowheads pointing to 
no nuclear β-catenin expression.  
e-h) Zoom in images of marked areas of OT main images (E-H) also with bold and empty 
arrowheads pointing to the differences of nuclear β-catenin expression in epithelial cells. 
There is a shift of the spatial β-catenin localization that spans from the cell nuclei, in 
epithelial cell either from KPC tumours or OT cultures treated with vehicle or Gemcitabine 
alone to the cell membrane upon treatment with ATRA or Gemcitabine and ATRA. Scale bar 
10 µm. 
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Supplementary Figure 11: The combination treatment affects the lumen formation and 
apico-basal polarity of cancer cells. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Ezrin antibody (red) and an anti-Cytokeratin 
antibody (green) to identify epithelial cells.  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm. 
 a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to Ezrin cell membrane expression in cancer cells and empty arrowheads pointing 
to loss of membranous Ezrin expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences in Ezrin expression in cancer cells. Ezrin 
expression is reduced in cancer cells of KPC mice tumours or OT cultures, after the 
combination treatment (Gemcitabine with ATRA). Scale bar 10 µm. 
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Supplementary Figure 12: ATRA alone or in combination with Gemcitabine nuclear 
Twist1 expression within cancer cells.  
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Twist1 antibody (red) and an anti-Cytokeratin 
antibody (green).  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with same 
antibodies as KPC mice sections. Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear Twist1 expression in epithelial cells expression and empty arrowheads 
pointing to loss of this nuclear Twist1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences of nuclear Twist1 expression in epithelial cells 
upon different treatment conditions. ATRA alone or in combination with Gemcitabine reduces 
nuclear Twist1 expression in epithelial cells, whilst in stellate cells nuclear Twist1 expression 
remains unaltered. Scale bar 10 µm. 
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Supplementary Figure 13: The combination treatment affects the nuclear 
translocation of transcription factor ZEB1 in cancer cells. 
A-D) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained with an anti-Zeb1 antibody (red) and an anti-αSMA antibody 
(green).  
E-H) Representative images of Capan1/PS1 organotypic (OT) sections stained with an anti-
E-cadherin antibody (red) and an anti-Zeb1 antibody (green). Scale bar 50 µm.  
a-d) Zoom in images of the marked areas of KPC main images (A-D) with bold arrowheads 
pointing to nuclear Zeb1 expression within epithelial cells and empty arrowheads pointing to 
loss of nuclear Zeb1 expression.  
e-h) Zoom in images of the marked areas of OT main images (E-H) also with bold and 
empty arrowheads pointing to the differences of nuclear Zeb1 expression in epithelial cells 
upon different treatment conditions. ATRA in combination with Gemcitabine reduces nuclear 
Zeb1 expression in epithelial cells, whilst in stellate cells nuclear Zeb1 expression remains 
unaltered. Scale bar 10 µm. 
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Supplementary Figure 14: The combination treatment affects the Hedgehog signalling 
in cancer cells. 
A) Representative images of tumour sections from LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre mice (KPC mice) stained by immuno-histochemistry with an anti-Gli1 antibody. Zoom in 
images show the clear expression of nuclear and cytoplasmic Gli1 in ductal cells sections 
from untreated or Gemcitabine treated mice in comparison to a reduction of Gli1 expression 
in cancer cells of ATRA/Gemcitabine treated mice.  
B) Representative images of OT sections stained by immuno-histochemistry with an anti-
Gli1 antibody. Zoom in images clearly show the reduction in Gli expression of cancer cells 
from Gemcitabine/ATRA treated OT cultures, which is in agreement with the differences in 
Gli1 expression also observed in KPC mice.  Scale bar 100 µm. Zoom in images: Scale bar 
10 µm. 
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Supplementary table 1: KPC mice characteristics at recruitment  
Treatment type Age (days) Tumour volume (mm3 on 2 days before 
treatment  as measured by ultrasound) 
Control 249 137.761 
Control 188 303.706 
Control 170 326.367 
Control 117 163.306 
Control 120 195.04 
Control 128 149.467 
Gemcitabine 211 124.714 
Gemcitabine 200 274.747 
Gemcitabine 189 232.725 
Gemcitabine 177 284.779 
Gemcitabine 176 149.722 
Gemcitabine 102 191.824 
ATRA 216 156.138 
ATRA 177 302.217 
ATRA 243 327.712 
ATRA 223 211.803 
ATRA 150 160.042 
ATRA + Gemcitabine 119 324.267 
ATRA + Gemcitabine 171 234.933 
ATRA + Gemcitabine 185 263.636 
ATRA + Gemcitabine 218 495.181 
ATRA + Gemcitabine 204 239.703 
ATRA + Gemcitabine 124 343.271 
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Supplementary table 2: Table of antibodies  
Sections 
species 
origin 
Antibody 
Catalogue 
reference 
Incubation 
period 
Antigen 
retrieval 
method 
IF (or IHC) 
dilution 
Organotypic 
sections 
(anti-human) 
Rabbit Cytokeratin DAKO Z0662 1h, RT HIER 1:200 
Mouse Fibronectin SIGMA F0916 ON, 40C Pepsin 1:100 
Mouse Ki67 DAKO M7240 1h, RT HIER 1:100 
Mouse αSMA DAKO M0851 1h, RT HIER 1:300 
Rabbit CC3 
Cell signaling 
D175 
1h, RT HIER 1:400 (IHC) 
Rabbit Gli1* 
Chemicon 
AB3444 
1h, RT 
HIER 1:300 (IHC) 
Mouse E-Cadherin Abcam ab1416 ON, 40C HIER 
1:100 
Rabbit RAR-β* Abcam ab53161 1h, RT 
HIER 1:200 (IHC) 
Mouse Twist1* Abcam ab50887 ON, 40C HIER 
1:100 
Rabbit Zeb1* 
Santa cruz sc-
25388 
ON, 40C HIER 
1:500 
Mouse FGF2* Millipore 05-118 
ON, 40C HIER 
1:100 
Rabbit FGFR1* Abcam ab10646 
ON, 40C HIER 
1:500 
Rabbit SFRP4* 
Santa cruz sc-
30152 
1h, RT 
N.A. 1:50 (IHC) 
Mouse Ezrin* BD 10603 
ON, 40C HIER 
1:200 
Mouse β-Catenin* BD 610154 
ON, 40C HIER 
1:200 
KPC mouse 
sections 
(anti-mouse) 
Rabbit CK8 Abcam ab59400 ON, 40C or 
1h, RT 
HIER 1:100 
Rabbit Fibronectin  Abcam ab23750 1h, RT HIER 1:200 (IHC) 
Rabbit Ki67 Abcam ab15580 1h, RT HIER  1:150 
Mouse αSMA  SIGMA F3777 ON, 40C HIER 1:500 
Rabbit CC3 Cell signaling 1h, RT HIER 1:400 (IHC) 
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D175 
Rat Endomucin Santa Cruz Sc-
65495 
1h, RT HIER 1:100 
Rabbit Glut1 Millipore 07-1401 ON, 40C HIER 1:250 
ON: overnight; 1h: one hour, RT; room temperature; 
HIER: Heat Induced Epitope Retrieval (citrate buffer pH6) 
N.A.: not applicable  
*: used also in mouse 
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